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(57) ABSTRACT 
Provided are monoquaternary ammonium compounds which 
are modulators of nicotinic acetylcholine receptors. Also 
provided are methods of using the compounds for modulat-
ing the function of a nicotinic acetylcholine receptor, and for 
the prevention and/or treatment of central nervous system 
disorders, substance use and/or abuse, and gastrointestinal 
tract disorders. 
10 Claims, No Drawings 
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MONO QUATERNARY AMMONIUM SALTS 
AND METHODS FOR MODULATING 
NEURONAL NICOTINIC ACETYLCHOLINE 
RECEPTORS 
2 
central nervous system are the homomeric receptors labeled 
by [3H]methyllycaconitine (MLA), which has high affinity 
for the a7 nicotinic receptor subtype. Nicotinic receptor 
subtypes can be studied using functional assays, such as 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a divisional of U.S. application Ser. 
5 NIC-evoked neurotransmitter release (e.g., [3H]dopamine 
(DA) release, [3 H]norepinephrine (NE) release, [3 H]sero-
tonin (5-HT) release, [3H]garmna-aminobutyric acid 
(GABA) release and [3 H]glutamate release) from super-
fused rat brain slices. Nicotinic receptors are located in the 
10 
cell body and terminal areas of these neurotransmitter sys-
tems. NIC facilitates neurotransmitter release from nerve 
terminals. 
No. 12/304,955, which is a National Stage ofPCTIUS2007/ 
014192, filed on Jun. 15, 2007, which claims benefit of U.S. 
Provisional Application No. 60/814,423, filed Jun. 16, 2006, 
which are expressly incorporated herein by reference herein. 
IDENTIFICATION OF FEDERAL FUNDING 
The present invention was supported by Grant NIH 
U19DA017548 from the National Institutes of Health, and 
therefore the govermnent may have rights in the invention. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of 
15 interest in developing novel, subtype-selective agonists and/ 
or antagonists. Some of these agonists are currently being 
evaluated in clinical trials for cognitive enhancement and 
neuroprotective effects, potentially beneficial for disease 
states such as Alzheimer's and Parkinson's disease. 
FIELD OF THE INVENTION 
The invention relates to monoquatemary armnonium salts 
and their use in modulating nicotinic acetylcholine recep-
tors. 
BACKGROUND OF THE INVENTION 
S(-)-nicotine (NIC) activates presynaptic and postsynap-
20 
25 
tic neuronal nicotinic receptors that evoke the release of 30 
neurotransmitters from presynaptic terminals and that 
modulate the depolarization state of the postsynaptic neu-
ronal membrane, respectively. Thus, nicotine produces its 
effect by binding to a family of ligand-gated ion channels, 
stimulated by acetylcholine (ACh) or nicotine which causes 35 
the ion channel to open and cations to flux with a resulting 
rapid (millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of two types 
of subunits, a and ~' and assemble as heteromeric receptors 
with the general stoichiometry of 2a and 3~ or as homo- 40 
meric receptors with Sa subunits. Nine subtypes of the a 
subunit (a2 to a10) and three subtypes of the~ unit (~2 to 
~4) are found in the central nervous system. The most 
common nicotinic receptor subtype in the brain is composed 
of two a4 and three ~2 subunits, i.e., a4~2. These subunits 45 
display different, but overlapping, patterns of expression in 
the brain. Examples of heteromeric receptor subtypes 
include a4~2, a3~2, a3~4, a6~2, a4a5~2, a6a5~2, 
a4a6~2, a4~2~4, a3~2~4, and others. The predominant 
homomeric subtype includes a7, but other combinations 50 
have also been proposed. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 55 
sequence at the subunit level and from the multiple combi-
nations of assemblies of subunits into functional receptor 
proteins, which affords a wide diversity of pharmacological 
specificity. 
In spite of the extensive diversity in neuronal nicotinic 60 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3 H]ACh. It has 
been estimated that over 90% of [3 H]NIC binding in the 65 
brain is due to association with the heteromeric receptor that 
is composed of a4 and ~2 subunits. Also abundant in the 
SUMMARY OF THE INVENTION 
In one embodiment, compounds corresponding to the 
following structure are provided. 
(I) 
A 1 , A2 , A3 , A4 , and A5 are independently selected from 
nitrogen or carbon, provided that when nitrogen is present, 
the nitrogen does not have an R substituent attached. 
R1 , R2 , R3 , R4 , and R5 are each independently selected 
from the group consisting of hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
heterocycle, substituted heterocycle, halo, cyano, and nitro, 
orR 1 and R 2 orR 2 and R3 together with the carbons to which 
they are attached independently form a three to eight-
member cycloalkane, substituted cycloalkane, cycloalkene, 
substituted cycloalkene, aryl, substituted aryl, heterocycle 
with one to three hetero atoms in the ring, or substituted 
heterocycle with one to three hetero atoms in the ring. 
Z1 is absent or is selected from the group consisting of 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
phenylene, substituted phenylene, alkoxy, and substituted 
alkoxy. 
Z2 is selected from the group consisting of alkyl, substi-
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub-
stituted alkenyl, alkynyl, substituted alkynyl, arylene, sub-
stituted arylene, heterocycle, substituted heterocycle, 
alkoxy, and substituted alkoxy. 
Z3 is selected from is selected from hydrogen, alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub-
stituted aryl, heterocycle, and substituted heterocycle. 
US 9,550,753 B2 
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x- is an inorganic or organic anion. 
In another embodiment, a composition is provided com-
prising a pharmaceutically acceptable carrier and a com-
pound as described above. 
In another embodiment, a method is provided for selec-
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effec-
tive amount of a compound as described above to a mam-
malian subject in need thereof. 
In another embodiment, a method is provided for pre- 10 
venting and/or treating a central nervous system associated 
disorder comprising administering a therapeutically effec-
tive amount of a compound as described above to a mam-
malian subject in need thereof. 
4 
The term "agonist" refers to a substance which interacts 
with a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term "partial agonist" refers to a substance which 
interacts with and activates a receptor to a lesser degree than 
an agonist. 
The term "antagonist" refers to a substance which inter-
acts with and decreases the extent or duration of a physi-
ological response of that receptor. 
The terms "disorder," "disease," and "condition" are used 
inclusively and refer to any status deviating from normal. 
The term "central nervous system associated disorders" 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated with the alteration of normal 
neurotransmitter release in the brain. 
In another embodiment, a method is provided for pre- 15 
venting and/or treating substance use and/or abuse compris-
ing administering a therapeutically effective amount of a 
compound as described above to a mammalian subject in 
need thereof. The term "lower alkyl" refers to straight or branched 
20 chain alkyl radicals having in the range of 1 to 4 carbon In another embodiment, a method is provided for pre-
venting and/or treating gastrointestinal tract disorders com-
prising administering a therapeutically effective amount of a 
compound as described above to a mammalian subject in 
need thereof. 
atoms. 
The term "alkyl" refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and "substituted alkyl" 
Other methods, features and advantages of the present 
invention will be or become apparent to one with skill in the 
art upon examination of the following detailed descriptions. 
25 refers to alkyl radicals further bearing one or more substitu-
ents including, but not limited to, hydroxy, alkoxy (of a 
lower alkyl group), mercapto (of a lower alkyl group), aryl, 
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino, It is intended that all such additional methods, features and 
advantages be included within this description, be within the 
scope of the present invention, and be protected by the 30 
accompanying claims. 
DETAILED DESCRIPTION OF THE 
INVENTION 
35 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 40 
describe particular embodiments of the present invention, 
and is in no way intended to limit the scope of the present 
invention as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms "a," "an," and "the" include plural 45 
references unless the context clearly dictates otherwise. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meanings as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. All publications cited herein are incor- 50 
porated herein by reference in their entirety for the purpose 
of describing and disclosing the methodologies, reagents, 
and tools reported in the publications that might be used in 
connection with the invention. Nothing herein is to be 
construed as an admission that the invention is not entitled 55 
to antedate such disclosure by virtue of prior invention. 
The term "nicotinic acetylcholine receptor" refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine which also bind to nicotine. The term "nico-
tinic acetylcholine receptor" includes the term "neural nico- 60 
tinic acetylcholine receptor." 
The terms "subtype of nicotinic acetylcholine receptor," 
and "nicotinic acetylcholine receptor subtype" refer to vari-
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or het- 65 
eromeric complex, or multiple homomeric or heteromeric 
complexes. 
carboxyl, carbamate, sulfonyl, and sulfonamide. 
The term "cycloalkyl" refers to cyclic ring-containing 
moieties containing 3 to 8 carbon atoms, and "substituted 
cycloalkyl" refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term "alkenyl" refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon 
double bond and having 2 to 19 carbon atoms, and "substi-
tuted alkenyl" refers to alkenyl groups further bearing one or 
more substituents as set forth above. 
The term "alkynyl" refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon 
triple bond and having 2 to 19 carbon atoms, and "substi-
tuted alkynyl" refers to alkynyl moieties further bearing one 
or more substituents as set forth above. 
The term "aryl" refers to aromatic groups having 6 to 24 
carbon atoms, and "substituted aryl" refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term "heterocyclic" refers to cyclic moieties contain-
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and "substituted heterocyclic" 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term "halogen" refers to fluoride, chloride, bromide 
or iodide groups. It is understood that in all substituted 
groups defined above, polymers arrived at by defining 
substituents with further substituents to themselves (e.g. 
substituted aryl having a substituted aryl group as a sub-
stituent which is itself substituted with a substituted aryl 
group, etc.) are not intended for inclusion herein. In such 
cases, the maximum number of such substituents is three. 
That is to say that each of the above definitions is con-
strained by a limitation that, for example, substituted aryl 
groups are limited to -substituted aryl-(substituted aryl)-
substituted aryl. 
US 9,550,753 B2 
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Compounds of the present invention are mono quaternary 
ammonium salts corresponding to Formula (I): 
6 
methyl unsaturated azetidine, methyl unsaturated N-methyl 
azetidine, methyl piperidine, methyl N-methyl piperidine, 
methyl unsaturated piperidine, methyl unsaturated N-methyl 
(I) 5 
piperidine, methyl azepane, methyl N-methyl azepane, 
methyl unsaturated azepane, methyl unsaturated N-methyl 
azepane, methyl azocane, methyl N-methyl azocane, methyl 
A\ A2 , A3 , A4 , and As are independently selected from 
nitrogen or carbon, provided that when nitrogen is present, 
the nitrogen does not have an R substituent attached. 
R1 , R2 , R3 , R4 , and Rs are each independently selected 
from the group consisting of hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
heterocycle, substituted heterocycle, halo, cyano, and nitro, 
orR 1 and R 2 orR 2 and R3 together with the carbons to which 
they are attached independently form a three to eight-
member cycloalkane, substituted cycloalkane, cycloalkene, 
substituted cycloalkene, aryl, substituted aryl, heterocycle 
with one to three hetero atoms in the ring, or substituted 
heterocycle with one to three hetero atoms in the ring. 
Z1 is absent or is selected from the group consisting of 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
phenylene, substituted phenylene, alkoxy, and substituted 
alkoxy. 
Z2 is selected from the group consisting of alkyl, substi-
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, sub-
stituted alkenyl, alkynyl, substituted alkynyl, arylene, sub-
stituted arylene, heterocycle, substituted heterocycle, 
alkoxy, and substituted alkoxy. 
Z3 is selected from is selected from hydrogen, alkyl, 
substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub-
stituted aryl, heterocycle, and substituted heterocycle. 
x- is an inorganic or organic anion. 
For example, R\ R2 , R3 , R4 , and Rs include hydrogen, 
methyl, ethyl, propyl, butyl, trifluoromethyl, pyrrolidine, 
N-alkyl pyrrolidine (for example where the alkyl chain is 
methyl, ethyl or propyl), unsaturated pyrrolidine, unsatu-
rated N-alkyl pyrrolidine (for example where the alkyl chain 
unsaturated azocane, methyl unsaturated N-methyl azocane, 
methyl-1-aza-bicyclo [3 .2 .1] octane, methy 1-1-aza -bicyclo 
[2.2.1]heptane, 8-methyl-8-aza-bicyclo[3.2.1]octane, and 
10 methyl-1-aza-tricyclo[3.3.1.1 3 .7]decane. 
As another example, when R1 and R2 , or R2 and R3 
together with the carbons to which they are attached, inde-
pendently form a three to eight-membered ring, that ring 
may be a heterocycle containing up to three hetero atoms 
15 (for example nitrogen, oxygen or sulfur) in the ring, and 
further may be substituted with one or more substituents. For 
example, possible rings include benzene, pyridine, pyran, 
indene, isoindene, benzofuran, isobenzofuran, benzo[b ]thio-
phene, benzo[c]thiophene, indole, indolenine, isoindole, 
20 cyclopental[b ]pyridine, pyrano[3,4-b ]pyrrole, indazole, 
indoxazine, benzoxazole, anthranil naphthalene, tetralin, 
decalin, chromene, coumarin, chroman-4-one, isocoumarin, 
isochromen-3-one, quinoline, isoquinoline, ciunoline, qui-
nazoline, naphthyridine, pyrido[3,4-b ]-pyridine, pyridol[3, 
25 2-b ]pyridine, pyrido[ 4,3-b ]-pyridine, benzoxazine, anthra-
cene, phenanthrene, phenalene, fluorene, carazole, xanthene, 
acnidine, octahydro-[!]pyridine, 1-methy loctahydro-[ 1] 
pyridine, octahydroindole, 1-methyloctahydro-indole, octa-
hydro-cyclopenta[b ]pyrrole, 1-methyloctahydro-cyclopenta 
30 [b ]pyrrole, decahydroquinoline, or 
1-methyldecahydroquinoline. 
As a further example, heterocycles formed by A1 , A2 , A3 , 
A4 , and As in combination with R1 , R2 , R3 , R4 , and Rs 
include pyridine, quinoline, 5,6,7,8-tetrahydroquinoline, 
35 isoquinoline, tetrahydroisoquinoline, pyrazine, pyrimidine, 
pyridazine, and triazine, as well as substituted forms thereof. 
Z1 for example includes alkyl (for example butyl or 
pentyl), cis-alkenyl; trans-alkenyl; substituted cis-alkenyl; 
substituted trans-alkenyl; alkynyl (for example but-3-ynyl or 
40 pent-4-ynyl). 
Z2 for example includes cis-alkenyl, trans-alkenyl, sub-
stituted cis-alkenyl, and substituted trans-alkenyl. 
x- for example includes Cl-, Br-, I-, N02 -, HS04 -, 
SO 4 -, HPO 4 -, PO 4 2 -, ethanesulfonate, trifluoromethane sul-
45 fate, p-toluenesulfonate, benzenesulfonate, salicylate, pro-
prionate, ascorbate, aspartate, fumarate, galactarate, 
maleate, citrate, glutamate, glycolate, lactate, malate, 
maleate, tartrate, oxalate, succinate, or similar pharmaceu-
tically acceptable organic acid addition salts, including the 
50 pharmaceutically acceptable salts listed in the Journal of 
Pharmaceutical Sciences volume 66, page 2, 1977, which 
are hereby incorporated by reference. The above salt forms 
may be in some cases hydrates or solvates with alcohols and 
other solvents. 
is methyl, ethyl or propyl), aziridine, N-methyl aziridine, 
azetidine, N-methyl azetidine, unsaturated azetidine, unsatu-
rated N-methyl azetidine, piperidine, N-methyl piperidine, 
unsaturated piperidine, unsaturated N-methyl piperidine, 55 
azepane, N-methyl azepane, unsaturated azepane, unsatu-
rated N-methyl azepane, azocane, N-methyl azocane, 
unsaturated azocane, unsaturated N-methyl azocane, l-aza-
bicyclo[3.2.1]octane, l-aza-bicyclo[2.2.1]heptane, 
8-methyl-8-aza-bicyclo[3.2.1]octane, 1-aza-tricyclo 
[3.3.1.1 3 .7]decane, methyl cycloalkyl, methyl substituted 
cycloalkyl, methylpyrrolidine, methyl N-alkyl pyrrolidine 
(for example where the alkyl chain is methyl, ethyl or 
propyl), methyl unsaturated pyrrolidine, methyl unsaturated 
N-alkyl pyrrolidine (for example where the alkyl chain is 
methyl, ethyl or propyl), methyl aziridine, methyl N-methyl 
aziridine, methyl azetidine, methyl N-methyl azetidine, 
In a compound of Formula (I), preferably A1 , A2 , A3 , A4 , 
and As are carbon. 
In a compound of Formula (I), preferably R1 is hydrogen, 
alkyl, or forms a six membered ring with A I, A 2 and R 2 and 
with R1 and R2 providing four carbon atoms. More prefer-
60 ably, R 1 is selected from hydrogen, methyl, forms a six 
membered ring with A 1 , A 2 and R 2 and with R 1 and R 2 
providing four unsaturated carbon atoms, or forms a phenyl 
group with A I, A2 and R2 . 
In a compound of Formula (I), preferably R2 is hydrogen, 
65 alkyl, aryl, 3-hydroxypropyl, 1-methyl-2-pyrrolidinyl, halo, 
forms a six membered ring with A 1 , A 2 and R 1 and with R 1 
and R2 providing four carbon atoms, or forms a six mem-
US 9,550,753 B2 
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bered ring withA2 , A3 and R3 and with R2 and R3 providing 
four carbon atoms. More preferably, R2 is hydrogen, methyl, 
ethyl, butyl, phenyl, 3-hydroxypropyl, 1-methyl-2-pyrrolidi-
nyl, bromo, forms a six membered ring with A\ A2 and R1 
and with R1 and R2 providing four unsaturated carbon 
atoms, forms a phenyl group with A 1 , A 2 and R 1 , forms a six 
membered ring with A2 , A3 and R3 and with R2 and R3 
providing four unsaturated carbon atoms, or forms a phenyl 
group with A2 , A3 and R3 . 
In a compound of Formula (I), preferably R3 is hydrogen, 
alkyl, or forms a six membered ring withA2 , A3 and R2 and 
with R2 and R3 providing four carbon atoms. More prefer-
ably, R3 is hydrogen, methyl, forms a six membered ring 
with A2 , A3 and R2 and with R2 and R3 providing four 
unsaturated carbon atoms, or forms a phenyl group withA2 , 
A3 and R2 . 
In a compound of Formula (I), preferably R4 is hydrogen 
or alkyl. More preferably, R4 is hydrogen or methyl. 
In a compound of Formula (I), preferably R5 is hydrogen. 
In a compound of Formula (I), preferably Z1 is absent, or 
is alkyl, alkynyl, or alkoxy. More preferably, Z1 is absent, 
butyl, but-3-ynyl, pentyl, pent-4-ynyl or 2-ethoxy. 
In a compound of Formula (I), preferably Z2 is alkyl, 
arylenyl or alkoxy. More preferably, Z2 is hexyl, octyl, 
dodecyl, tridecyl, para-phenylene, or 2-ethoxy. 
In a compound of Formula (I), preferably Z3 is alkyl, 
alkynyl, aryl or heterocyclic. More preferably Z3 is propyl, 
butyl, but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl. 
In a compound of Formula (I), preferably X is a halogen. 
More preferably, X is chloride, bromide or iodide. 
In one embodiment, the compound of Formula (I) is 
defined wherein A\ A2 , A3 , A4 , andA5 are carbon; wherein 
R 1 is hydrogen, methyl, forms a six membered ring with A 1 , 
A2 and R2 and with R1 and R2 providing four unsaturated 
carbon atoms, or forms a phenyl group with A\ A2 and R2 ; 
wherein R2 is hydrogen, methyl, ethyl, butyl, phenyl, 3-hy-
droxypropyl, 1-methyl-2-pyrrolidinyl, bromo, forms a six 
membered ring with A1 , A2 and R1 and with R1 and R2 
providing four unsaturated carbon atoms, forms a phenyl 
group with A 1 , A 2 and R 1 , forms a six membered ring with 
A 2 , A3 and R3 and with R 2 and R3 providing four unsaturated 
carbon atoms, or forms a phenyl group withA2 , A3 and R3 ; 
ID# Rl R2 
GZ-565A H Me 
GZ-565B Me H 
GZ-565C H H 
GZ-566A H Me 
GZ-566B H Me 
GZ-566C Me H 
8 
wherein R3 is hydrogen, methyl, forms a six membered ring 
with A2 , A3 and R2 and with R2 and R3 providing four 
unsaturated carbon atoms, or forms a phenyl group withA2 , 
A3 and R2 ; wherein R4 is hydrogen or methyl; wherein R5 is 
hydrogen; wherein Z1 is absent, butyl, but-3-ynyl, pentyl, 
pent-4-ynyl or 2-ethoxy; wherein Z2 is hexyl, octyl, dodecyl, 
tridecyl, para-phenylene, or 2-ethoxy; wherein Z3 is propyl, 
butyl, but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl; and 
wherein X is chloride, bromide or iodide. 
10 
In another embodiment, the compound of Formula (I) is 
defined wherein A\ A2 , A3 , A4 , andA5 are carbon; wherein 
R1 is hydrogen, methyl, forms a six membered ring withA1 , 
A2 and R2 and with R1 and R2 providing four unsaturated 
carbon atoms, or forms a phenyl group withA1 , A2 and R2 ; 
wherein R2 is hydrogen, methyl, ethyl, 3-hydroxypropyl, 
15 1-methyl-2-pyrrolidinyl, bromo, forms a six membered ring 
with A\ A 2 and R 1 and with R 1 and R 2 providing four 
unsaturated carbon atoms, forms a phenyl group with A 1 , A 2 
and R\ forms a six membered ring withA2 , A3 and R3 and 
with R2 and R3 providing four unsaturated carbon atoms, or 
20 forms a phenyl group with A2 , A3 and R3 ; wherein R3 is 
hydrogen, methyl, forms a six membered ring with A2 , A3 
and R2 and with R2 and R3 providing four unsaturated 
carbon atoms, or forms a phenyl group withA2 , A3 and R2 ; 
wherein R4 is hydrogen or methyl; wherein R5 is hydrogen; 
25 
wherein Z1 is absent, butyl, but-3-ynyl, pent-4-ynyl or 
2-ethoxy; wherein Z2 is hexyl, octyl, dodecyl, tridecyl, 
para-phenylene, or 2-ethoxy; wherein Z3 is propyl, butyl, 
but-1-ynyl, hex-1-ynyl, phenyl, or 3-pyridinyl; and wherein 
30 
X is chloride, bromide or iodide. 
In another embodiment, the compound of Formula (I) is 
defined wherein A\ A2 , A3 , A4 , andA5 are carbon; wherein 
R1 is hydrogen, methyl, or forms a phenyl group withA1 , A2 
and R2 ; wherein R2 is hydrogen, methyl, butyl, phenyl, 
1-methyl-2-pyrrolidinyl, forms a phenyl group with A\ A2 
35 
and R\ or forms a phenyl group withA2 ,A3 andR3 ; wherein 
R3 is hydrogen, methyl, or forms a phenyl group withA2 , A3 
and R2 ; wherein R4 is hydrogen or methyl; wherein R5 is 
hydrogen; wherein Z1 is pentyl or pent-4-ynyl; wherein Z2 
is para-phenylene; wherein Z3 is phenyl; and wherein X is 
40 bromide. 
Exemplary compounds for this application are presented 
in Table 1. 
TABLE 1 
R3 R4 zl z2 z3 X 
H H but-3-ynyl p-phenyl phenyl bromide 
H H but-3-ynyl p-phenyl phenyl bromide 
Me H but-3-ynyl p-phenyl phenyl bromide 
H Me but-3-ynyl p-phenyl phenyl bromide 
Me H but-3-ynyl p-phenyl phenyl bromide 
Me H but-3-ynyl p-phenyl phenyl bromide 
GZ-567A phenyl with R2 phenyl with R 1 H H but-3-ynyl p-phenyl phenyl bromide 
GZ-567B H phenyl with R3 phenyl with R2 H but-3-ynyl p-phenyl phenyl bromide 
GZ-567C H !-methyl-2-pyrrolidinyl H H but-3-ynyl p-phenyl phenyl bromide 
GZ-568A H butyl H H but-3-ynyl p-phenyl phenyl bromide 
ID# 
GZ-568B 
GZ-568C 
GZ-573A 
GZ-573B 
GZ-573C 
GZ-574A 
GZ-574B 
GZ-574C 
GZ-575A 
GZ-575B 
GZ-575C 
GZ-576A 
GZ-576B 
ZZ-1-101 
ZZ-1-104 
ZZ-1-107 
ZZ-1-137A 
ZZ-1-137C 
ZZ-1-137D 
ZZ-1-137F 
ZZ-1-26 
ZZ-1-29 
ZZ-1-40A 
ZZ-1-40B 
ZZ-1-40C 
ZZ-1-40D 
ZZ-1-40E 
ZZ-1-40F 
ZZ-1-40G 
ZZ-1-40H 
ZZ-1-401 
ZZ-1-40J 
ZZ-1-47 
ZZ-1-48 
ZZ-1-49 
ZZ-1-50 
ZZ-1-70 
ZZ-1-71 
ZZ-1-71A 
ZZ-1-71B 
ZZ-1-71C 
ZZ-1-71D 
ZZ-1-71E 
ZZ-1-71F 
ZZ-1-71H 
ZZ-1-72 
ZZ-1-73 
ZZ-1-74 
ZZ-1-76 
ZZ-1-77 
ZZ-1-77A 
ZZ-1-77B 
ZZ-1-77C 
H 
H 
H 
Me 
H 
H 
H 
Me 
phenyl with R 2 
H 
H 
H 
H 
H 
Me 
Me 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
Me 
Me 
ring with R2 , R 1 & 
R2 provide 4 
unsaturated carbons 
H 
H 
H 
H 
H 
Me 
Me 
H 
H 
H 
Me 
H 
H 
H 
Me 
H 
H 
H 
H 
H 
H 
H 
H 
H 
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TABLE !-continued 
phenyl 
H 
Me 
H 
H 
Me 
Me 
H 
phenyl with R1 
phenyl with R3 
!-methyl-2-pyrrolidinyl 
butyl 
H 
3-hydroxypropyl 
H 
H 
Me 
Me 
Me 
ring with R3 , R2 & 
R3 provide 4 
nnsaturated carbons 
H 
!-methyl-2-pyrrolidinyl 
Me 
H 
Me 
Me 
H 
H 
ring with Rl, R1 & 
R2 provide 4 
nnsaturated carbons 
ring with R3 , R2 & 
R3 provide 4 
nnsaturated carbons 
!-methyl-2-pyrrolidinyl 
hydroxypropyl 
Me 
H 
H 
H 
Me 
H 
Me 
H 
H 
Me 
Me 
H 
ring with R3 , R2 & 
R3 provide 4 
nnsaturated carbons 
Me 
Me 
ring with R3 , R2 & 
R3 provide 4 
H 
H 
H 
H 
Me 
H 
Me 
Me 
H 
phenyl with R 2 
H 
H 
H 
H 
H 
Me 
H 
H 
Me 
ring with R2 , R2 & 
R3 provide 4 
unsaturated carbons 
Me 
H 
H 
Me 
Me 
H 
H 
Me 
H 
ring with R2 , R2 & 
R3 provide 4 
unsaturated carbons 
H 
H 
H 
Me 
H 
Me 
H 
Me 
H 
H 
Me 
Me 
H 
Me 
ring with R2 , R2 & 
R3 provide 4 
unsaturated carbons 
H 
Me 
ring with R2 , R2 & 
R3 provide 4 
nnsaturated carbons unsaturated carbons 
Et 
hydroxypropyl 
Me 
H 
Br 
H 
H 
H 
[[H]]Me 
H 
H 
H 
H 
H 
H 
Me 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
Me 
H 
H 
H 
H 
H 
H 
H 
Me 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
Me 
H 
H 
but-3-ynyl 
but-3-ynyl 
butyl 
butyl 
butyl 
butyl 
butyl 
butyl 
butyl 
butyl 
butyl 
butyl 
butyl 
propyl 
propyl 
propyl 
methoxy 
methoxy 
methoxy 
methoxy 
methoxy 
methoxy 
methoxy 
methoxy 
methoxy 
methoxy 
prop-2-ynyl 
prop-2-ynyl 
but-3-ynyl 
but-3-ynyl 
but-3-ynyl 
but-3-ynyl 
but-3-ynyl 
but-3-ynyl 
but-3-ynyl 
10 
z3 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl phenyl 
p-phenyl butyl 
p-phenyl butyl 
p-phenyl butyl 
dodecyl 3-pyridinyl 
dodecyl 3-pyridinyl 
dodecyl 3-pyridinyl 
dodecyl 3-pyridinyl 
hexyl hex-1-ynyl 
hexyl hex-1-ynyl 
2-ethoxy hexyl 
2-ethoxy hexyl 
2-ethoxy hexyl 
2-ethoxy hexyl 
2-ethoxy hexyl 
2-ethoxy hexyl 
2-ethoxy hexyl 
2-ethoxy 
2-ethoxy 
2-thoxy 
heptyl 
heptyl 
heptyl 
heptyl 
p-phenyl 
p-phenyl 
p-phenyl 
p-phenyl 
p-phenyl 
p-phenyl 
p-phenyl 
p-phenyl 
p-phenyl 
hexyl 
hexyl 
hexyl 
phenyl 
phenyl 
phenyl 
phenyl 
butyl 
butyl 
propyl 
propyl 
propyl 
propyl 
propyl 
propyl 
propyl 
Me prop-2-ynyl p-phenyl 
H prop-2-ynyl p-phenyl 
H prop-2-ynyl p-phenyl 
butyl 
butyl 
butyl 
prop-2-ynyl p-phenyl 
prop-2-ynyl p-phenyl 
butyl 
butyl 
X 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
iodide 
iodide 
chloride 
chloride 
chloride 
chloride 
chloride 
chloride 
chloride 
chloride 
chloride 
chloride 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
bromide 
H 
H 
H 
H 
H 
undecyl 3-pyridinyl bromide 
undecyl 3-pyridinyl bromide 
undecyl 3-pyridinyl bromide 
US 9,550,753 B2 
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TABLE !-continued 
ID# Rl R2 R3 R4 zl z2 z3 X 
ZZ-1-77D H Me Me H undecyl 3-pyridinyl bromide 
ZZ-1-77E H Me H Me undecyl 3-pyridinyl bromide 
ZZ-1-77F H !-methyl-2-pyrrolidinyl H H undecyl 3-pyridinyl bromide 
ZZ-1-94 H Me H H propyl p-phenyl butyl bromide 
ZZ-1-95 H H Me H propyl p-phenyl butyl bromide 
ZZ-1-96 H Me H Me propyl p-phenyl butyl bromide 
ZZ-1-97 H Me Me H propyl p-phenyl butyl bromide 
ZZ-1-98 H ring with R3, R2 & ring with R2, R2 & H propyl p-phenyl butyl bromide 
R3 provide 4 R3 provide 4 
nnsaturated carbons unsaturated carbons 
ZZU-1 Me H H 
ZZU-2 H Me H 
ZZU-3 Me H Me 
ZZU-4 H Me H 
ZZU-5 H Me Me 
ZZU-6 Me H H 
ZZU-7 H Me H 
ZZU-8 H H Me 
Exemplary compounds of the present invention include: 
2-methyl-1-(8-phenyl-octyl)-pyridinium bromide; 
3-methyl-1-(8-phenyl-octyl)-pyridinium bromide; 2,4-dim-
ethyl-1-(8-phenyl-octyl)-pyridinium bromide; 4-methyl-1-
(8-phenyl-octyl)-pyridinium bromide; 1-dodec-7 -ynyl-2-
methyl-pyridinium iodide; 1-dodec-7-ynyl-3-methyl-
pyridinium iodide; 1-dodec-7-ynyl-4-methyl-pyridinium 
iodide; 1-dodec-7 -ynyl-2,4-dimethyl-pyridinium iodide; 
1-dodec-7 -ynyl-3,5-dimethyl-pyridinium iodide; 1-dodec-7-
ynyl-3,4-dimethyl-pyridinium iodide; 1-dodec-9-ynyl-2-
methyl-pyridinium bromide; 1-dodec-9-ynyl-3-methyl-pyri-
dinium bromide; 1-dodec-9-ynyl-4-methyl-pyridinium 
bromide; 1-[ 4-( 4-butyl-phenyl)-butyl]-2-methyl-pyridinium 
bromide; 1-[ 4-( 4-butyl-phenyl)-butyl]-3-methyl-pyridinium 
bromide; 1-[ 4-( 4-butyl-phenyl)-butyl]-4-methyl-pyridinium 
bromide; 2-[ 4-( 4-butyl-phenyl)-butyl]-5,6, 7 ,8-tetrahydro-
isoquinolinium bromide; 1-[ 4-( 4-butyl-phenyl)-butyl]-3-(3-
hydroxy-propyl)-pyridinium bromide; 1-[ 4-( 4-butyl-phe-
nyl)-butyl]-2,4-dimethyl-pyridinium bromide; 1-[ 4-( 4-
butyl-phenyl)-butyl]-3,4-dimethyl-pyridinium bromide; 
1-[ 4-( 4-butyl-phenyl)-butyl]-3,5-dimethyl-pyridinium bro-
mide; 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3-methyl-pyri-
dinium bromide; 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-4-
methyl-pyridinium bromide; 1-[ 4-( 4-butyl-phenyl)-but-3-
ynyl]-3-ethyl-pyridinium bromide; 2-[ 4-( 4-butyl-phenyl)-
but-3-ynyl]-5,6,7,8-tetrahydro-isoquinolinium bromide; 
1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3,4-dimethyl-pyridinium 
bromide; 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3,5-dimethyl-
pyridinium bromide; 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3-
(3-hydroxy-propyl)-pyridinium bromide; 3-methyl-1-[13-
(3-pyridinyl)-tridecyl]-pyridinium bromide; 3,4-dimethyl-1-
[13-(3-pyridinyl)-tridecyl]-pyridinium bromide; 3,5-
dimethyl-1-[13-(3-pyridinyl)-tridecyl]-pyridinium bromide; 
2-[ 13 -(3 -pyridiny 1)-tridecyl]-5, 6, 7, 8-tetrahydro-isoquino-
linium bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pent-4-ynyl]-2-
H hexyl hex-1-ynyl iodide 
H hexyl hex-1-ynyl iodide 
H hexyl hex-1-ynyl iodide 
Me hexyl hex-1-ynyl iodide 
H hexyl hex-1-ynyl iodide 
H octyl but-1-ynyl bromide 
H octyl but-1-ynyl bromide 
H octyl but-1-ynyl bromide 
methyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-
4-ynyl]-3-methyl-pyridinium bromide; 1-[5-(1 ,1 '-biphenyl-
35 4-yl)-pent-4-ynyl]-4-methyl-pyridinium bromide; 1-[5-(1, 
1 '-biphenyl-4-y I )-pent -4-yny 1]-2,4-dimethy 1-pyridinium 
bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pent-4-ynyl]-3,4-dim-
ethyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-4-
ynyl]-3,5-dimethyl-pyridinium bromide; 1-[5-(1, 1 '-biphe-
40 nyl-4-yl)-pent-4-ynyl]-quinolinium bromide; 2-[5-(1,1 '-
biphenyl-4-yl)-pent-4-ynyl]-isoquinolinium bromide; 1-[5-
(1, 1 '-biphenyl-4-yl)-pent-4-ynyl]-3-butyl-pyridinium 
bromide; 1-[5-(1,1'-biphenyl-4-yl)-pent-4-ynyl]-3-phenyl-
pyridinium bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pent-4-ynyl]-
45 1-pyridinium bromide; 1-[5-(1,1 '-biphenyl-4-yl)-pentyl]-2-
methyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-3-methyl-pyridinium bromide; 1-[5-(1 ,1 '-biphenyl-
4-yl)-pentyl]-4-methyl-pyridinium bromide; 1-[5-(1,1 '-
biphenyl-4-yl)-pentyl]-2,4-dimethyl-pyridinium bromide; 
so 1-[ 5-(1, 1 '-biphenyl-4-yl)-pentyl]-3,4-dimethyl-pyridinium 
bromide; 1-[ 5-(1, 1 '-biphenyl-4-yl)-pentyl]-3,5-dimethyl-
pyridinium bromide; 1-[5-(1 ,1 '-biphenyl-4-yl)-pentyl]-qui-
nolinium bromide; 2-[5-(1 ,1 '-biphenyl-4-yl)-pentyl]-isoqui-
nolinium bromide; 1-[5-(1,1 '-biphenyl-4-yl)-pentyl]-3-
55 butyl-pyridinium bromide; 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-pyridinium bromide; 1-dodec-7 -ynyl-3-(1-methyl-
2-pyrrolidinyl)-pyridinium iodide; 3-methyl-1-[ 4-( 4-propyl-
phenyl)-pent-4-ynyl]-pyridinium bromide; 2-methyl-1-[ 4-
(4-propyl-phenyl)-pent-4-ynyl]-pyridinium bromide; 
60 4-methyl-1-[ 4-( 4-propyl-phenyl)-pent-4-ynyl]-pyridinium 
bromide; 3,4-dimethyl-1-[ 4-( 4-propyl-phenyl)-pent-4-
ynyl]-pyridinium bromide; 3,5-dimethyl-1-[ 4-( 4-propyl-
phenyl)-pent-4-ynyl]-pyridinium bromide; 2,4-dimethyl-1-
[ 4-( 4-propyl-phenyl)-pent-4-ynyl]-pyridinium bromide; 
65 2-[ 4-( 4-propyl-phenyl)-pent-4-ynyl]-5,6, 7 ,8-tetrahydro-iso-
quinolinium bromide; 1-[5-(1, 1 '-biphenyl-4-yl)-pent-4-
ynyl]-3-(1-methyl-2-pyrrolidinyl)-pyridinium bromide; 
US 9,550,753 B2 
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1-[ 5-(1, 1 '-biphenyl-4-yl)-pentyl]-3-(1-methyl-2-pyrrolidi-
nyl)-pyridinium bromide; 1-[2-(2-hexoxy-ethoxy)-ethyl]-3-
methyl-pyridinium chloride; 1-[2-(2-hexoxy-ethoxy)-ethyl]-
4-methyl-pyridinium chloride; 1-[2-(2-hexoxy-ethoxy)-
ethyl]-3,4-dimethyl-pyridinium chloride; 1-[2-(2-hexoxy-
ethoxy )-ethyl]-3,5-dimethyl-pyridinium chloride; 1-[2-(2-
hexoxy-ethoxy )-ethyl]-2-methyl-pyridinium chloride; 1-[2-
(2-hexoxy-ethoxy)-ethyl]-2,4-dimethyl-pyridinium 
14 
mitter from a central nervous system tissue. The neurotrans-
mitter affected may include dopamine, norepinephrine, sero-
tonin, gamma-aminobutyric acid, or glutamate. 
Central nervous system disorders which may be treated 
according to the method of the present invention include 
Alzheimer's disease, dementia, cognitive dysfunctions (in-
cluding disorders of attention, focus and concentration), 
attention deficit disorders, affective disorders, extrapyrami-
dal motor function disorders, Parkinson's disease, progres-chloride; 1-[2-(2-hexoxy-ethoxy )-ethyl]-5,6, 7 ,8-tetrahydro-
quinolinium chloride; 2-[2-(2-hexoxy-ethoxy)-ethyl]-5,6,7, 
8-tetrahydro-isoquinolinium chloride; 1-[2-(2-hexoxy-
ethoxy)-ethyl]-3-methyl-pyridinium chloride; 1-[2-(2-
hexoxy-ethoxy )-ethy 1]-3 -methy 1-pyridinium chloride; 
10 sive supramolecular palsy, Huntington's disease, Gilles de Ia 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis-
orders, dysregulation of food intake, disorders of nocicep-
tion, pain, mood and emotional disorders, depression, panic 
3-methyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium bro-
mide; 4-methyl-1-[12-(3-pyridinyl)-dodecyl]-pyridinium 15 
anxiety, psychosis, schizophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/or treating substance 
use and/or abuse comprising administering to a mmalian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I). In such a method, the compound 
bromide; 3-bromo-1-[12-(3-pyridinyl)-dodecyl]-pyridinium 
bromide; 3,4-dimethyl-1-[12-(3-pyridinyl)-dodecyl]-pyri-
dinium bromide; 3,5-dimethyl-1-[12-(3-pyridinyl)-dode-
cyl]-pyridinium bromide; and 3-(1-methyl-2-pyrrolidinyl)-
1-[ 12-(3-pyridinyl)-dodecyl]-pyridinium bromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as well as racemic 
mixtures. The compounds can be separated into substan-
tially optically pure compounds. 
20 of Formula (I) may selectively bind to one or more subtypes 
of nicotinic acetylcholine receptor. The compound of For-
mula (I) may act as an agonist or partial agonist of nicotinic 
acetylcholine receptor function. Hence the compound of 
Formula (I) may increase or prolong the release of a neu-
The compounds of the invention are nicotinic acetylcho-
line receptor agents. Thus, they may augment or inhibit 
[ 3H]nicotine binding, [3H]MLA binding, evoke or inhibit 
neurotransmitter release, and/or evoke or inhibit the flux of 
ions through the nicotinic receptor. 
25 rotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gamma-aminobutyric acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 
30 Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam-
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 35 
compound of Formula (I) may selectively bind to one or 
more subtypes of nicotinic acetylcholine receptor. The com-
pound of Formula (I) may act as an agonist or partial agonist 
of nicotinic acetylcholine receptor function. Hence the com-
pound of Formula (I) may increase or prolong the release of 40 
a neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gma-aminobutyric acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 45 
Hence the compound of Formula (I) may decrease the extent 
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutyric acid, or glutamate. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet-
amine abuse, cocaine abuse, or alcohol abuse. 
In another embodiment, the present invention is directed 
to a method for preventing and/or treating gastrointestinal 
tract disorders comprising administering to a mmalian 
subject in need thereof a therapeutically effective amount of 
a compound of Formula (I). In such a method, the compound 
of Formula (I) may selectively bind to one or more subtypes 
of nicotinic acetylcholine receptor. The compound of For-
mula (I) may act as an agonist or partial agonist of nicotinic 
acetylcholine receptor function. Hence the compound of 
Formula (I) may increase or prolong the release of a neu-
or duration of the release of a neurotransmitter from a central 
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutyric acid, or glutamate. 
In another embodiment, the present invention is directed 
to a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effec-
tive amount of a compound of Formula (I). In such a 
method, the compound of Formula (I) may selectively bind 
50 rotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi-
nephrine, serotonin, gamma-aminobutyric acid, or gluta-
mate. Alternatively, the compound of Formula (I) may act as 
an antagonist of nicotinic acetylcholine receptor function. 
55 Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
to one or more subtypes of nicotinic acetylcholine receptor. 
The compound of Formula (I) may act as an agonist or 
partial agonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may increase or prolong 60 
the release of a neurotransmitter from a central nervous 
system tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act as an antagonist of nicotinic acetylcholine 65 
receptor function. Hence the compound of Formula (I) may 
decrease the extent or duration of the release of a neurotrans-
nervous system tissue. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-amin-
obutyric acid, or glutamate. 
Gastrointestinal disorders which may be treated according 
to the method of the present invention include irritable 
bowel syndrome, colitis, diarrhea, constipation, gastric acid 
secretion or ulcers. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along with suit-
able carriers or excipients, as is well known in the art. For 
example, a pharmaceutical composition of the invention 
US 9,550,753 B2 
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may include a conventional additive, such as a stabilizer, 
buffer, salt, preservative, filler, flavor enhancer and the like, 
as known to those skilled in the art. Exemplary buffers 
include phosphates, carbonates, citrates and the like. Exem-
plary preservatives include EDTA, EGTA, BHA, BHT and 
the like. 
16 
may optionally contain gum arabic, talc, polyvinyl pyrroli-
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identification or to characterize 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-fit capsules made of gelatin, as well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
An effective amount of such agents can readily be deter-
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro-
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e.g., Gennaro, A. R., ed. 
(1995) Remington's Pharmaceutical Sciences. 
10 glycerol or sorbitol. The push-fit capsules can contain the 
active ingredients in admixture with filler such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap-
sules, the active compounds may be dissolved or suspended 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, nasal, or intestinal admin-
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as well as intrath-
ecal, direct intraventricular, intravenous, intraperitoneal, 
intranasal, or intraocular injections. The agent or composi-
tion thereof may be administered in a local rather than a 
systemic manner. For example, a suitable agent can be 20 
delivered via injection or in a targeted drug delivery system, 
such as a depot or sustained release formulation. 
15 in suitable liquids, such as fatty oils, liquid paraffin, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dos-
ages suitable for such administration. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods well-known in 
the art, such as by conventional mixing, dissolving, granu- 25 
lating, dragee-making, levigating, emulsifYing, encapsulat-
ing, entrapping, or lyophilizing processes. As noted above, 
the compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 30 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin-
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in 
physiologically compatible buffers such as Hanks' solution, 35 
Ringer's solution, or physiological saline buffer. For trans-
mucosal or nasal administration, penetrants appropriate to 
the barrier to be permeated are used in the formulation. Such 
penetrants are generally known in the art. In a preferred 
embodiment of the present invention, the present com- 40 
pounds are prepared in a formulation intended for oral 
administration. For oral administration, the compounds can 
be formulated readily by combining the active compounds 
with pharmaceutically acceptable carriers well known in the 
art. Such carriers enable the compounds of the invention to 45 
be formulated as tablets, pills, dragees, capsules, liquids, 
gels, syrups, slurries, suspensions and the like, for oral 
ingestion by a subject. The compounds may also be formu-
lated in rectal compositions such as suppositories or reten-
tion enemas, e.g., containing conventional suppository bases 50 
such as cocoa butter or other glycerides. 
Pharmaceutical preparations for oral use can be obtained 
as solid excipients, optionally grinding a resulting mixture, 
and processing the mixture of granules, after adding suitable 
auxiliaries, if desired, to obtain tablets or dragee cores. 55 
Suitable excipients are, in particular, fillers such as sugars, 
including lactose, sucrose, mannitol, or sorbitol; cellulose 
preparations such as, for example, maize starch, wheat 
starch, rice starch, potato starch, gelatin, gum tragacanth, 
methyl cellulose, hydroxypropylmethyl-cellulose, sodium 60 
carboxymethylcellulose, and/or polyvinylpyrrolidone 
(PVP). If desired, disintegrating agents may be added, such 
In one embodiment, the compounds of the present inven-
tion can be administered transdermally, such as through a 
skin patch, or topically. In one aspect, the transdermal or 
topical formulations of the present invention can addition-
ally comprise one or multiple penetration enhancers or other 
effectors, including agents that enhance migration of the 
delivered compound. Transdermal or topical administration 
could be preferred, for example, in situations in which 
location specific delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently deliv-
ered in the form of an aerosol spray presentation from 
pressurized packs or a nebulizer, with the use of a suitable 
propellant, e.g., dichlorodifluoromethane, trichlorofluo-
romethane, dichlorotetrafluoroethane, carbon dioxide, or 
any other suitable gas. In the case of a pressurized aerosol, 
the appropriate dosage unit may be determined by providing 
a valve to deliver a metered amount. Capsules and cartridges 
of, for example, gelatin, for use in an inhaler or insufllator 
may be formulated. These typically contain a powder mix of 
the compound and a suitable powder base such as lactose or 
starch. 
Compositions formulated for parenteral administration by 
injection, e.g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, with an added preservative. The 
compositions may take such forms as suspensions, solu-
tions, or emulsions in oily or aqueous vehicles, and may 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Formulations for parenteral admin-
istration include aqueous solutions or other compositions in 
water-soluble form. 
Suspensions of the active compounds may also be pre-
pared as appropriate oily injection suspensions. Suitable 
lipophilic solvents or vehicles include fatty oils such as 
sesame oil and synthetic fatty acid esters, such as ethyl 
oleate or triglycerides, or liposomes. Aqueous injection 
suspensions may contain substances that increase the vis-
cosity of the suspension, such as sodium carboxymethyl 
cellulose, sorbitol, or dextran. Optionally, the suspension 
may also contain suitable stabilizers or agents that increase 
the solubility of the compounds to allow for the preparation 
of highly concentrated solutions. Alternatively, the active 
ingredient may be in powder form for constitution with a 
suitable vehicle, e.g., sterile pyrogen-free water, before use. as the cross-linked polyvinyl pyrrolidone, agar, or alginic 
acid or a salt thereof such as sodium alginate. Also, wetting 
agents such as sodium dodecyl sulfate may be included. 
As mentioned above, the compositions of the present 
65 invention may also be formulated as a depot preparation. 
Dragee cores are provided with suitable coatings. For this 
purpose, concentrated sugar solutions may be used, which 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu-
US 9,550,753 B2 
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larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated with suitable poly-
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
18 
tration utilized. The exact formulation, route of administra-
tion, and dosage should be chosen, according to methods 
known in the art, in view of the specifics of a subject's 
condition. 
Suitable carriers for the hydrophobic molecules of the 
invention are well known in the art and include co-solvent 
systems comprising, for example, benzyl alcohol, a nonpolar 
surfactant, a water-miscible organic polymer, and an aque-
ous phase. The co-solvent system may be the VPD co-
solvent system. VPD is a solution of3% w/v benzyl alcohol, 
8% w/v of the nonpolar surfactant polysorbate 80, and 65% 
w/v polyethylene glycol300, made up to volume in absolute 
ethanol. The VPD co-solvent system (VPD:5W) consists of 
VPD diluted 1: 1 with a 5% dextrose in water solution. This 
co-solvent system is effective in dissolving hydrophobic 
compounds and produces low toxicity upon systemic admin-
istration. Naturally, the proportions of a co-solvent system 
may be varied considerably without destroying its solubility 
and toxicity characteristics. Furthermore, the identity of the 
co-solvent components may be varied. For example, other 
low-toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction size of polyethylene glycol may 
The amount of agent or composition administered will, of 
course, be dependent on a variety of factors, including the 
sex, age, and weight of the subject being treated, the severity 
of the afl.liction, the manner of administration, and the 
judgment of the prescribing physician. 
10 The present compositions may, if desired, be presented in 
a pack or dispenser device containing one or more unit 
dosage forms containing the active ingredient. Such a pack 
or device may, for example, comprise metal or plastic foil, 
15 such as a blister pack. The pack or dispenser device may be 
accompanied by instructions for administration. Composi-
tions comprising a compound of the invention formulated in 
a compatible pharmaceutical carrier may also be prepared, 
placed in an appropriate container, and labeled for treatment 
20 of an indicated condition. 
These and other embodiments of the present invention 
will readily occur to those of ordinary skill in the art in view 
of the disclosure herein, and are specifically contemplated. 
be varied, other biocompatible polymers may replace poly-
ethylene glycol, e.g., polyvinyl pyrrolidone, and other sug- 25 
ars or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic 
molecules may be employed. Liposomes and emulsions are 
well known examples of delivery vehicles or carriers for 
hydrophobic drugs. Liposomal delivery systems are dis- 30 
cussed above in the context of gene-delivery systems. Cer-
tain organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus-
tained-release systems, such as semi-permeable matrices of 35 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained-
release materials are established and available to those of 
skill in the art. Sustained-release capsules may, depending 
on their chemical nature, release the compounds for a few 40 
weeks up to over 100 days. Depending on the chemical 
nature and the biological stability of the therapeutic reagent, 
additional strategies for stabilization may be employed. 
For any composition used in the present methods of 
treatment, a therapeutically effective dose can be estimated 45 
initially using a variety of techniques well known in the art. 
For example, in a cell culture assay, a dose can be formu-
lated in animal models to achieve a circulating concentration 
range that includes the IC50 as determined in cell culture. 
Dosage ranges appropriate for human subjects can be deter- 50 
mined, for example, using data obtained from cell culture 
assays and other animal studies. 
A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 
EXAMPLES 
The invention is further understood by reference to the 
following examples, which are intended to be purely exem-
plary of the invention. The present invention is not limited 
in scope by the exemplified embodiments, which are 
intended as illustrations of single aspects of the invention 
only. Any methods that are functionally equivalent are 
within the scope of the invention. Various modifications of 
the invention in addition to those described herein will 
become apparent to those skilled in the art from the fore-
going description. Such modifications fall within the scope 
of the appended claims. 
Example 1 
Synthesis of compound 
2-methyl-1-(8-phenyl-octyl)-pyridinium bromide 
ACN,reflux 
XJ 
e 
Br 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu-
tion of 2-picoline (3 mmol) in acetonitrile, and the solution 
60 mixture was refluxed for 24 hours. The acetonitrile was 
or a prolongation of survival in a subject. Toxicity and 55 
therapeutic efficacy of such molecules can be determined by 
standard pharmaceutical procedures in cell cultures or 
experimental animals, e.g., by determining the LD50 (the 
dose lethal to 50% of the population) and the ED 5 0 (the dose 
therapeutically effective in 50% of the population). The dose 
ratio of toxic to therapeutic effects is the therapeutic index, 
which can be expressed as the ratio LD50/ED50 . Agents that 
exhibit high therapeutic indices are preferred. 
Dosages preferably fall within a range of circulating 
concentrations that includes the ED50 with little or no 65 
toxicity. Dosages may vary within this range depending 
upon the dosage form employed and the route of adminis-
removed in a vacuum, and the resulting residue was parti-
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no picoline was left in 
the aqueous layer. The resulting aqueous solution of the 
product was extracted with chloroform. The chloroform was 
removed to afford the product (70%). 1HNMR (300 MHz, 
CDC13, ppm) 9.74 (d, lH), 8.35 (m, lH), 7.96 (m, lH), 7.86 
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(d, lH), 7.15-7.25 (m, 4H), 4.92 (t, 2H), 2.95 (s, 3H), 
1.88-1.98 (m, 2H), 1.54-1.64 (m, 2H), 1.39-1.49 (m, 2H), 
1.25-1.38 (br, 6H). 
Example 2 
Synthesis of compound 
3 -methy 1-1-(8-pheny 1-octyl )-pyridinium bromide 
Br u 
N 
ACN,reflux 
20 
The resulting aqueous solution of the product was extracted 
with chloroform. The chloroform was removed to afford the 
product (70%). 1HNMR (300 MHz, CDC13, ppm), 9.50 (d, 
lH), 7.70 (d, lH), 7.60 (s, lH), 7.10-7.30 (dd, lH), 4.78 (t, 
5 2H), 2.84 (s, 3H), 2.54-2.60 (m, 5H), 1.80-1.92 (m, 2H), 
1.50-1.60 (br, 2H), 1.20-1.45 (br, 6H). 
Example 4 
10 Synthesis of compound 
4-methyl-1-(8-phenyl-octyl)-pyridinium bromide 
15 
Br 0 Q 
20 1 
~ 
~ N 
e # 
N 
ACN,reflux 
# 
Br 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu- 25 
tion of 3-picoline (3 mmol) in acetonitrile, and the solution 
refluxed for 24 hours. The acetonitrile was removed in a 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no pi co line was left in the aqueous layer. The 30 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (76%). 1HNMR (300 MHz, CDC13, ppm) 9.40 (s, 
lH), 9.22 (d, lH), 8.02 (d, lH), 7.96 (dd, lH), 7.12-7.22 (dd, 
4H), 4.94 (t, 2H), 2.62 (s, 3H), 2.56 (t, 2H), 1.94-2.04 (m, 35 
2H), 1.50-1.60 (m, 2H), 1.20-1.40 (br, 8H). 13CNMR, 
145.68, 144.65, 142.87, 142.37, 139.79, 128.55, 128.40, 
127.89, 125.76, 62.20, 36.19, 32.29, 31.73, 29.53, 29.44, 
29.33, 26.40, 19.11. 
() N 
e 
Br 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu-
tion of 4-picoline (3 mmol) in acetonitrile, and the solution 
was refluxed for 24 hours. The acetonitrile was removed in 
vacuum and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (78%). 1HNMR (300 MHz, CDC13, ppm) 9.26 (d, 
2H), 7.84 (d, 2H), 7.14-7.28 (dd, 4H), 4.90 (t, 2H), 2.62 (s, 
Example 3 
Synthesis of compound 
2,4-dimethyl-1-(8-phenyl-octyl)-pyridinium bromide 
40 3H), 2.56 (t, 2H), 1.92-2.02 (m, 2H), 1.50-1.60 (m, 2H), 
1.20-1.40 (br, 8H). 13CNMR, 158.92, 144.28, 142.86, 
128.95, 128.56, 128.40, 125.76, 61.61, 36.19, 32.15, 31.71, 
29.53, 29.42, 29.31, 26.37, 22.63. 
45 
~ 50 Br 
ACN,reflux 
xr 55 ~ ~ 
e 
# 
Br 
60 
(8-Bromo-octyl)-benzene (1 mmol) was added to a solu-
tion of2,4-lutidine (3 mmol) in acetonitrile, and the solution 
refluxed for 24 hours. The acetonitrile was removed in a 
vacuum and the resulting residue was partitioned between 65 
ether and water. The aqueous layer was washed extensively 
with ether until no 2,4-lutidine was left in the aqueous layer. 
Example 5 
Synthesis of compound 
1-dodec-7-ynyl-2-methyl-pyridinium iodide 
KI!Butanone, 
reflux 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas-
sium iodide (3 mmol) and 2-picoline (3 mmol) in butanone. 
room temperature. The butanone was removed in a vacuum, 
and the resulting residue was partitioned between water and 
US 9,550,753 B2 
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ethyl ether. The aqueous layer was washed extensively with 
ether until no 2-picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (85%). 1HNMR (300 MHz, CDC13, ppm) 9.62 (d, 5 
lH), 8.39 (dd, lH), 7.99 (m, lH), 7.91 (d, lH), 4.88 (t, 2H), 
2.97 (s, 3H), 2.12-2.20 m, 4H), 1.90-2.00 (m, 2H), 1.32-1.58 
(m, 8H), 0.88 (t, 3H). 
22 
The mixture was refluxed for 3 days and cooled to room 
temperature, filtrated. The butanone was removed in a 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed 
extensively with ether until no 4-picoline was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was 
removed to afford the product (87%). 1HNMR (300 MHz, 
CDC13, ppm), 9.28 (d, 2H), 7.92 (d, 2H), 4.92 (t, 2H), 2.68 
Example 6 10 (s, 3H), 1.96-2.18 (m, 6H), 1.32-1.50 (br, 10H), 0.88 (t, 3H). 
Synthesis of compound 
1-dodec-7-ynyl-3-methyl-pyridinium iodide 
KI!Butanone, 
reflux 
15 
20 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas-
sium iodide (3 mmol) and 3-picoline (3 mmol) in butanone. 30 
The mixture was refluxed for 3 days and cooled to room 
temperature, filtrated. The butanone was removed in a 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed 
extensively with ether until no 3-picoline was left in the 35 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was 
removed to afford the product (82% ). 1 HNMR (300 MHz, 
CDC13, ppm) 9.36 (s, lH), 9.18 (d, lH), 8.24 (d, lH), 8.00 
(dd, lH), 4.92 (t, 2H), 2.62 (s, 3H), 1.95-2.18 (m, 6H), 40 
1.15-1.25 (br, 10H), 0.90 (t, 3H); 13CNMR, 145.51, 144.12, 
144.78, 139.46, 127.56, 80.44, 79.42, 61.75, 31.72, 31.16, 
28.65, 28.04, 25.52, 21.92, 18.75, 18.55, 18.40, 13.63. 
Example 8 
Synthesis of compound 
1-dodec-7 -ynyl-2,4-dimethyl-pyridinium iodide 
Cl 
Kl/ 
Butanone, 
reflux 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas-
sium iodide (3 mmol) and 2,4-lutidine (3 mmol) in 
butanone. The mixture was refluxed for 3 days and cooled to 
room temperature, filtrated. The butanone was removed in a 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed 
extensively with ether until no 2,4-lutidine was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was 
removed to afford the product (84%). 1HNMR (300 MHz, 
CDC13, ppm), 9.40 (d, lH), 7.75 (d, lH), 7.66 (s, lH), 4.78 
(t, 3H), 2.88 (s, 3H), 2.60 (s, 3H), 2.05-2.15 (br, 4H), 
1.80-2.00 (br, 2H), 1.30-1.50 (br, 10H), 0.86 (t, 3H); 
13CNMR, 156.73, 153.05, 145.84, 136.61, 127.27, 80.86, 
Example 7 45 79.85, 58.12, 31.54, 30.94, 39.09, 26.17, 22.39, 22.30, 
21.03, 18.96, 18.79, 14.02. 
Synthesis of compound 
1-dodec-7-ynyl-4-methyl-pyridinium iodide 
Cl 0 N 
KI! 
Butanone, 
reflux 
12-Chloro-dodec-5-yne (1 mmol) was mixed with potas-
sium iodide (3 mmol) and 4-picoline (3 mmol) in butanone. 
50 
55 
65 
Example 9 
Synthesis of compound 
1-dodec-7 -ynyl-3,5-dimethyl-pyridinium iodide 
Cl u N 
KI/Butanone, 
reflux 
A r~ 
e I 
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-continued 12-Chloro-dodec-5-yne (1 nnnol) was mixed with potas-
sium iodide (3 nnnol) and 3,5-lutidine (3 nnnol) in 
butanone. The mixture was refluxed for 3 days and cooled to 
room temperature, filtrated. The butanone was removed in 
vacuum, and the resulting residue was partitioned between 5 
water and ethyl ether. The aqueous layer was washed 
extensively with ether until no 3,5-lutidine was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was 
removed to afford the product (78% ). 1 HNMR (300 MHz, 
CDC13, ppm), 9.06 (s, 2H), 8.00 (s, lH), 4.86 (t, 3H), 2.48 
12-Bromo-dodec-3-yne (1 nnnol) was added to a solution 
of 2-picoline (3 nnnol) in acetonitrile, and the solution was 
10 refluxed for 24 hours. The acetonitrile was removed in 
vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no 2-picoline was left in the aqueous layer. 
The resulting aqueous solution of the product was extracted 
(s, 3H), 1.98-2.16 (m, 6H), 1.32-1.48 (br, 10H), 0.88 (t, 3H); 
13CNMR, 146.12, 141.38, 138.64, 80.43, 79.53, 61.46, 
31.70, 31.17, 28.68, 28.07, 25.55, 21.92, 18.57, 18.42, 
13.63. 
Example 10 
15 with chloroform. The chloroform was removed to afford the 
product (70%). 1HNMR (300 MHz, CDC13, ppm), 9.68 (d, 
lH), 8.28 (m, lH), 7.96 (m, lH), 7.84 (d, lH), 4.94 (t, 2H), 
2.98 (s, 3H), 2.05-2.20 (m, 4H), 1.88-2.00 (m, 2H), 1.20-
1.60 (br, 10H), 1.10 (t, 3H). 
Synthesis of compound 20 
1-dodec-7 -ynyl-3,4-dimethyl-pyridinium iodide 
Cl & 
N 
25 
KI/Butanone, 
reflux 30 
Example 12 
Synthesis of compound 
1-dodec-9-ynyl-3-methyl-pyridinium bromide 
Br u N 
ACN,reflux 
e1 
k~ 
12-Bromo-dodec-3-yne (1 nnnol) was added to a solution 
40 of 3-picoline (3 nnnol) in acetonitrile, and the solution was 
refluxed for 24 hours. The acetonitrile was removed in a 
12-Chloro-dodec-5-yne (1 nnnol) was mixed with 
Sodium iodide (3 nnnol) and 3,4-lutidine (3 nnnol) in 
butanone. The mixture was refluxed for 3 days and cooled to 
room temperature, filtrated. The butanone was removed in 
vacuum, and the resulting residue was partitioned between 
water and ethyl ether. The aqueous layer was washed 
extensively with ether until no 3,4-lutidine was left in the 
aqueous layer. The resulting aqueous solution of the product 45 
was extracted with chloroform. The chloroform was 
removed to afford the product (72% ). 1 HNMR, (300 MHz, 
CDC13, ppm, ppm), 9.22 (s, lH), 9.04 (d, lH), 7.80 (d, lH), 
4.84 (t, 3H), 2.52 (s, 3H), 2.50 (s, 3H), 1.92-2.14 (m, 6H), 
1.28-1.45 (m, 10H), 0.84 (t, 3H). 13CNMR, 157.84, 143.39, 50 
141.81, 138.53, 128.72, 80.80, 79.90, 61.23, 32.03, 31.54, 
29.08, 28.48, 25.91, 22.30, 20.78, 18.96, 18.79, 17.44, 
14.02. 
Example 11 
Synthesis of 1-dodec-9-ynyl-2-methyl-pyridinium 
bromide 
ACN,reflux 
55 
60 
65 
vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no picoline was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (70%). 1HNMR (300 MHz, CDC13, ppm), 9.42 (s, 
lH), 9.24 (d, lH), 8.24 (d, lH), 8.00 (dd, lH), 4.95 (t, 2H), 
2.62 (s, 3H), 1.95-2.2 (m, 6H), 1.23-1.45 (br, 10H), 1.1 (t, 
3H); 13CNMR, 145.29, 144.24, 141.98, 139.42, 127.51, 
81.57, 79.26, 61.83, 31.90, 28.95, 28.92, 28.82, 28.62, 
26.02, 18.72, 18.63, 14.38, 12.40. 
Example 13 
Synthesis of compound 
1-dodec-9-ynyl-4-methyl-pyridinium bromide 
Br 0 N 
ACN,reflux 
US 9,550,753 B2 
25 
-continued 
e'Y 
~v 
12-Bromo-dodec-3-yne (1 mmol) was added to a solution 
of 4-picoline (3 mmol) in acetonitrile, and the solution was 10 
refluxed for 24 hours. The acetonitrile was removed in a 
vacuum, and the resulting residue was partitioned between 
ether and water. The aqueous layer was washed extensively 
with ether until no pi co line was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 15 
product (82%). 1HNMR (300 MHz, CDC13, ppm), 9.24 (d, 
2H), 7.86 (d, 2H), 4.90 (t, 2H), 2.64 (s, 3H), 1.95-2.16 (m, 
6H), 1.26-1.34 (br, 10H), 0.88 (t, 3H). 
26 
-continued 
~ ~~ 
e 
Br 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of 3-picoline (3 mmol) in acetonitrile and the 
solution refluxed for 24 hours. The acetonitrile was removed 
in vacuum, and the resulting residue was partitioned 
between ether and water. The aqueous layer was washed 
extensively with ether until no picoline was left in the 
aqueous layer. The resulting aqueous solution of the product 
was extracted with chloroform. The chloroform was 
removed to afford the product (75%). 1HNMR (300 MHz, 
CDC13, ppm), 9.32 (s, lH), 9.2 (d, 1=5.1, lH), 8.16 (d, 
Example 14 
Synthesis of 
1-[ 4-( 4-butyl-phenyl)-butyl]-2-methyl-pyridinium 
bromide 
20 1=5.1, 7.91 (m, lH), 7.07 (d, 1=8.4, 2H), 7.02 (d, 1=8.4, 2H), 
4.96 (t, 1=7.2, 2H), 2.52-2.64 (m, 7H), 2.00-2.06 (m, 2H), 
1.60-1.70 (m, 2H), 1.60-1.60 (m, 2H), 1.29-1.36 (m, 2H), 
0.90 (t, 1=7.2, 3H); 13CNMR, 145.62, 144.71, 142.37, 
Br 
ACN,reflux 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
25 140.84, 139.73, 138.32, 128.66, 128.48, 127.78, 61.82, 
35.54, 34.95, 34.05, 31.71, 27.93, 22.72, 19.07, 14.33. 
30 
Example 16 
Synthesis of compound 
1-[ 4-( 4-butyl-phenyl)-butyl]-4-methyl-pyridinium 
bromide 
to a solution of 2-picoline (3 mmol) in acetonitrile, and the 40 
solution was refluxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti-
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no 2-picoline was left in 
the aqueous layer. The resulting aqueous solution of the 45 
product was extracted with chloroform. The chloroform was 
removed to afford the product (74%). 1HNMR (300 MHz, 
CDC13, ppm), 9.69 (d, 1=6.6, lH), 8.25-8.30 (m, lH), 
7.90-7.95 (m, lH), 7.77 (d, 1=7.8, lH), 7.04-7.10 (m, 4H), 
4.92 (t, 7.5, 2H), 2.84 (s, 3H), 2.66 (t, 1=7.2, 2H), 2.56 (t, 50 
1=7.5, 2H), 1.89-1.98 (m, 2H), 1.78-1.86 (m, 2H), 1.51-1.59 
(m, 2H), 1.27-1.37 (m, 2H), 0.91 (t, 1=7.2, 3H). 
Br 0 
N 
ACN, 
reflux 
e'Y 
~v 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of 4-picoline (3 mmol) in acetonitrile, and the 
solution was refluxed for 24 hours. The acetonitrile was Example 15 
Synthesis of compound 
1-[ 4-( 4-butyl-phenyl)-butyl]-3-methyl-pyridinium 
bromide 
Br u 
N 
ACN,reflux 
55 
removed in a vacuum, and the resulting residue was parti-
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no picoline was left in 
the aqueous layer. The resulting aqueous solution of the 
product was extracted with chloroform. The chloroform was 
60 removed to afford the product (72%). 1HNMR (300 MHz, 
CDC13, ppm), 9.22 (d, 1=6.6, 2H), 7.79 (d, 1=6.6, 2H), 7.05 
(d, 1=8.4, 2H), 7.02 (d, 1=8.4, 2H), 4.90 (t, 1=7.5, 3H), 
2.51-2.63 (m, 7H), 1.96-2.06 (m, 2H), 1.58-1.68 (m, 2H), 
1.51-1.61 (m, 2H), 1.31-1.37 (m, 2H), 0.89 (t, 1=7.2, 3H); 
65 13CNMR, 158.91, 144.31, 140.83, 138.30, 128.92, 128.66, 
128.45, 61.26, 35.54, 34.95, 34.04, 31.61, 27.95, 22.73, 
22.57, 14.33. 
US 9,550,753 B2 
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Example 17 
Synthesis of 2-[ 4-( 4-butyl-phenyl)-butyl]-5,6, 7,8-
tetrahydro-isoquinolinium bromide 
~Br co ACN,reflux 10 
f ' N~ ~15 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
28 
Example 19 
Synthesis of compound 1-[ 4-( 4-butyl-phenyl)-bu-
tyl]-2,4-dimethyl-pyridinium bromide 
Br 
ACN,reflux 
'Y1( 
/)v 
e 
Br 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of2,4-lutidine (3 mmol) in acetonitrile, and the 
solution was refluxed for 24 hours, The acetonitrile was 
removed in a vacuum, and the resulting residue was parti-
tioned between ether and water, The aqueous layer was 
washed extensively with ether until no lutidine left in the 
aqueous layer, The resulting aqueous solution of the product 
was extracted with chloroform, The chloroform was 
removed to afford the product (79%), 1HNMR (300 MHz, 
CDC13, ppm), 9,51 (d, 1=6,2, lH), 7,67 (d, 1=6,2, lH), 7,54 
(s, lH), 7,05-7,07 (m, 4H), 4,83 (t, 1=7,2, 2H), 2,77 (s, 3H), 
2,64 (t, 1=7,2, 2H), 2,52-2,58 (m, 5H), L87-L92 (m, 2H), 
to a solution oftetrahydroisoquinoline (2 mmol) in acetoni-
trile, and the solution was refluxed for 24 hours, The 20 
acetonitrile was removed in vacuum, and the resulting 
residue was partitioned between ether and water, The aque-
ous layer was washed extensively with ether until no tetra-
hydroisoquinoline was left in the aqueous layer, The result-
ing aqueous solution of the product was extracted with 25 
chloroform, The chloroform was removed to afford the 
product (72%), 1HNMR (300 MHz, CDC13, ppm), 9,12 (s, 
lH), 8,85 (d, 1=6,0, lH), 7,61 (d, 1=6,0, lH), 7,02-7,08 (m, 
4H), 4,83 (t, 7,5, 3H), 2,92-2,94 (m, 4H), 2,61 (t, 1=7,5, 2H), 
2,54 (t, 1=7,5, 2H), L90-2,04 (m, 2H), L80-L90 (m, 4H), 30 
L62-L69 (m, 2H), L53-L62 (m, 2H), L29-L37 (m, 2H), 
0,90 (t, 1=7,2, 3H), 13CNMR, 157,94, 144,18, 140,82, 
140,64, 138,96, 138,37, 128,65, 128A8, 127,99, 6U6, 
35,54, 34,99, 34,05, 3L56, 29,92, 27,98, 26,69, 22,74, 
2L37, 14,33, 35 L76-L82 (m, 2H), L50-L58 (m, 2H), L29-L37 (m, 2H), 
0,91 (t, 1=7,8, 3H), 
Example 18 
Synthesis of 1-[ 4-( 4-butyl-phenyl)-butyl]-3-(3-hy-
droxy-propyl)-pyridinium bromide 
40 
~Br OJ
OH 
N::,. 45 
ACN,reflux 
f '\ Nn 
~OH5o 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of hydroxypropanylpyridine (2 mmol) in 
acetonitrile, and the solution was refluxed for 24 hours, The 55 
acetonitrile was removed in a vacuum, and the resulting 
residue was partitioned between ether and water, The aque-
ous layer was washed extensively with ether until no 
hydroxypropanylpyridine was left in the aqueous layer, The 
resulting aqueous solution of the product was extracted with 60 
chloroform, The chloroform was removed to afford the 
product (65%), 1HNMR (300 MHz, CDC13, ppm), 9A1 (s, 
lH), 8,85 (d, 1=6,3, lH), 8,26 (d, 1=8,1, lH), 7,89 (dd, 1=6,3, 
1=8,1, lH), 7,02-7,07 (m, 4H), 4,90 (t, 1=7,5, 2H), 3,59 (t, 
1=5A, 2H), 3,00 (t, 1=6,9, 2H), 2,62 (t, 1=7,2, 2H), 2,55 (t, 65 
1=7,8, 2H), L95-2,05 (m, 4H), L57-L69 (m, 2H), L50-L60 
(m, 2H), L29-L37 (m, 2H), 0,90 (t, 1=7,2, 3H), 
Example 20 
Synthesis of 1-[ 4-( 4-butyl-phenyl)-butyl]-3,4-dim-
ethyl-pyridinium bromide 
Br ex N 
ACN,reflux 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 
to a solution of3,4-lutidine (3 mmol) in acetonitrile, and the 
solution was refluxed for 24 hours, The acetonitrile was 
removed in a vacuum, and the resulting residue was parti-
tioned between ether and water, The aqueous layer was 
washed extensively with ether until no lutidine left in the 
aqueous layer, The resulting aqueous solution of the product 
was extracted with chloroform, The chloroform was 
removed to afford the product (79%), 1HNMR (300 MHz, 
CDC13, ppm), 9,20 (s, lH), 9,03 (d, 1=6,3, lH), 7,72 (d, 
1=6,3, lH), 7,00-7,07 (m, 4H), 4,87 (t, 1=7,5, 2H), 2,60 (t, 
1=7,8, 2H), 2,54 (t, 1=7,8, 2H), 2A9 (s, 3H), 2A6 (s, 3H), 
L99-2,04 (m, 2H), L50-L66 (m, 4H), L28-L36 (m, 2H), 
US 9,550,753 B2 
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0.90 (t, 1=7.5, 3H). 13CNMR 157.60, 143.56, 141.92, 
140.78, 138.40, 128.63, 128.57, 128.47, 61.00, 35.54, 34.98, 
34.04, 31.59, 27.96, 22.73, 20.66, 17.36, 14.31. 
30 
washed extensively with ether until no picoline was left in 
the aqueous layer. The resulting aqueous solution of the 
product was extracted with chloroform. The chloroform was 
removed to afford the product (77% ). 1 HNMR R (300 MHz, 
Example 21 
Synthesis of 1-[ 4-( 4-butyl-phenyl)-butyl]-3,5-dim-
ethyl-pyridinium bromide 
5 CDC13, ppm), 9.48 (s, lH), 9.33 (d, 1=6.6, lH), 8.24 (d, 
1=7.2, lH), 7.93 (dd, 1=6.6, 1=7.2, lH), 7.16 (d, 1=8.2, 2H), 
7.06 (d, 1=8.2, 2H), 5.21 (t, 1=6.0, 2H), 3.26 (t, 1=6.0, 2H), 
2.59 (s, 3H), 2.56 (t, 2H), 1.49-1.59 (m 2H), 1.25-1.37 (m, 
2H), 0.9 (t, 1=7.2, 3H); 13CNMR, 145.70, 144.78, 143.64, 
10 142.26, 138.98, 131.15, 128.32, 126.94, 118.92, 85.84, 
82.45, 59.90, 35.45, 33.28, 22.81. 22.24, 18.71, 13.89. 
Br 
~ [~ 
ACN,reflux 
15 
Example 23 
Synthesis of compound 1-[ 4-( 4-butyl-phenyl)-but-3-
yny 1]-4-methy 1-pyridinium bromide 
Br 0 
N 
ACN,reflux 
~ kV 
e Br 
1-(4-Bromo-butyl)-4-butyl-benzene (1 mmol) was added 25 
to a solution of3,5-lutidine (3 mmol) in acetonitrile, and the 
solution was refluxed for 24 hours. The acetonitrile was 
removed in a vacuum, and the resulting residue was parti-
tioned between ether and water. The aqueous layer was 
washed extensively with ether until no lutidine was left in 30 
the aqueous layer. The resulting aqueous solution of the 
product was extracted with chloroform. The chloroform was 
removed to afford the product (81% ). 1 HNMR (300 MHz, 
CDC13, ppm), 9.11 (s, 2H), 7.92 (s, lH), 7.00-7.06 (m, 4H), 
4.88 (t, 1=7.5, 2H), 2.51-2.62 (m, 7H), 1.99-2.05 (m, 2H), 35 
1.49-1.66 (m, 4H), 1.28-1.35 (m, 2H), 0.89 (t, 1=7.2, 3H). 
13CNMR, 146.17, 141.96, 140.81, 138.91, 138.40, 128.63, 
128.48, 61.60, 35.54, 34.98, 34.05, 31.68, 27.95, 22.72, 1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
40 added to a solution of 4-picoline (3 mmol) in acetonitrile, 
and the solution was refluxed for 24 hours. The acetonitrile 
18.88, 14.31. 
Example 22 
Synthesis of compound 1-[4-(4-butyl-phenyl)-but-3-
ynyl]-3-methyl-pyridinium bromide 
ACN,reflux 
Q 
~ 
N 
e Br 
was removed in vacuum, and the resulting residue was 
partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no picoline was left in 
45 the aqueous layer. The resulting aqueous solution of the 
product was extracted with chloroform. The chloroform was 
removed to afford the product (67%). 1HNMR (300 MHz, 
CDC13, ppm), 9.40 (d, 1=6.9, lH), 7.80 (d, lH), 7.17 (d, 
1=7.8, 2H), 7.06 (d, 1=7.8, 2H), 5.2 (t, 2H), 3.23 (t, 2H), 2.65 
50 (s, 3H), 2.56 (t, 1=7.8, 2H), 1.49-1.57 (m, 2H), 1.27-1.35 (m, 
2H), 0.90 (t, 1=7.5, 3H). 
55 
60 
Example 24 
Synthesis of 1-[4-( 4-butyl-phenyl)-but-3-ynyl]-3-
ethyl-pyridinium bromide 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3-picoline (3 mmol) in acetonitrile, 
and the solution was refluxed for 24 hours. The acetonitrile 65 
was removed in a vacuum, and the resulting residue was 
partitioned between ether and water. The aqueous layer was 
ACN,reflux 
US 9,550,753 B2 
31 
-continued 
~ ~~ 
e Br 
10 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3-ethylpyridine (3 mmol) in acetoni-
trile, and the solution was refluxed for 24 hours. The 
acetonitrile was removed in vacuum, and the resulting 
residue was partitioned between ether and water. The aque- 15 
ous layer was washed extensively with ether until no eth-
ylpyridine was left in the aqueous layer. The resulting 
aqueous solution of the product was extracted with chloro-
form. The chloroform was removed to afford the product 
(67%). lHNMR (300 MHz, CDC13, ppm), 9.43 (d, 1=6.0, 20 
lH), 9.41 (s, lH), 8.25 (d, 1=8.1, lH), 7.96 (dd, 1=6.0, 1=8.1, 
lH), 7.15 (d, 1=8.1, 2H), 7.06, d, 1=8.1, 2H), 5.26 (t, 1=6.0, 
2H), 3.26 (t, 1=6.0, 2H), 2.90 (q, 1=7.5, 2H), 2.56 (t, 1=8.1, 
2H), 1.49-1.59 (m, 2H), 1.27-1.37 (m, 5H), 0.90 (t, 1=7.2, 
3H); 13CNMR, 144.65, 144.46, 144.14, 143.65, 142.45, 25 
131.14, 128.30, 127.12, 118.87, 85.88, 82.45, 59.99, 35.45, 
33.27, 26.01, 22.85, 22.21, 14.26, 13.88. 
Example 25 
32 
Example 26 
Synthesis of 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3,4-
dimethyl-pyridinium bromide 
cc 
Br ----=--------'-• 
ACN,reflux 
cc N 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3-hydroxypropanylpyridine (2 mmol) 
in acetonitrile, and the solution was refluxed for 24 hours. 
The acetonitrile was removed in a vacuum, and the resulting 
residue was partitioned between ether and water. The aque-
ous layer was washed extensively with ether until no 
hydroxypropanylpyridine was left in the aqueous layer. The 
resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (60%). lHNMR (300 MHz, CDC13, ppm), 9.39 (s, 
lH), 9.13 (d, 1=6.3, lH), 7.70 (d, 1=6.3, lH), 7.17 (d, 1=8.1, 
2H), 7.07 (d, 1=8.1, 2H), 5.13 (t, 1=6.0, 2H), 3.23 (t, 1=6.0, 
2H), 2.57 (t, 1=7.8, 2H), 2.53 (s, 3H), 2.48 (s, 3H), 1.50-1.58 
(m, 2H), 1.28-1.37 (m, 2H), 0.90 (t, 1=7.2, 3H); 13CNMR, 
Synthesis of 2-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-5,6, 
7,8-tetrahydro-isoquinolinium bromide 
30 158.19, 143.98, 138.11, 131.53, 128.69, 128.05, 119.45, 
83.11, 59.60, 35.84, 33.64, 23.12, 22.62, 20.77, 17.35, 
14.23. 
Br co N 
ACN,reflux 
00 N 
e 
Br 
35 
40 
45 
50 
Example 27 
Synthesis of 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3,5-
dimethyl-pyridinium bromide 
ACN,reflux 
A 
~~ 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of 3,5-lutidine (2 mmol) in acetonitrile, 
55 and the solution was refluxed for 24 hours. The acetonitrile 
was removed in a vacuum, and the resulting residue was 
partitioned between ether and water. The aqueous layer was 
washed extensively with ether until no lutidine was left in 
the aqueous layer. The resulting aqueous solution of the 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of tetrahydroisoquinoline (2 mmol) in 
acetonitrile, and the solution was refluxed for 24 hours. The 
acetonitrile was removed in a vacuum, and the resulting 
residue was partitioned between ether and water. The aque-
ous layer was washed extensively with ether until no tetra-
hydroisoquinoline was left in the aqueous layer. The result-
ing aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (68%). lHNMR (300 MHz, CDC13, ppm), 9.30 (s, 60 
lH), 9.04 (d, 1=6.3, 2H), 7.62 (d, 1=6.3, lH), 7.18 (d, 1=8.4, 
2H), 7.06 (d, 1=8.4, 2H), 5.10 (t, 1=6.0, 3.21 (t, 1=6.0, 2H), 
2.94-2.96 (m, 2H), 2.56 (t, 1=8.1, 2H), 1.81-1.87 (m, 2H), 
1.49-1.56 (m, 2H), 1.27-1.34 (m, 2H), 0.89 (t, 1=7.2, 3H); 
13CNMR, 158.51, 144.59, 143.95, 140.93, 138.61, 131.55, 65 
128.71, 127.57, 119.46, 85.97, 83.23, 59.58, 35.86, 33.69, 
31.01, 26.70, 23.12, 22.63, 21.37, 14.28. 
product was extracted with chloroform. The chloroform was 
removed to afford the product (80%). 1HNMR (300 MHz, 
CDC13, ppm), 9.39 (s, lH), 9.13 (d, 1=6.3, lH), 7.70 (d, 
1=6.3, lH), 7.17 (d, 1=8.1, 2H), 7.07 (d, 1=8.1, 2H), 5.13 (t, 
1=6.0, 2H), 3.23 (t, 1=6.0, 2H), 2.57 (t, 1=7.8, 2H), 2.53 (s, 
3H), 2.48 (s, 3H), 1.50-1.58 (m, 2H), 1.28-1.37 (m, 2H), 
0.90 (t, 1=7.2, 3H); 13CNMR, 158.19, 143.98, 138.11, 
131.53, 128.69, 128.05, 119.45, 83.11, 59.60, 35.84, 33.64, 
23.12, 22.62, 20.77, 17.35, 14.23. 
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Example 28 
Synthesis of 1-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-3-(3-
hydroxy-propyl)-pyridinium bromide 
OJOH 
~Br N ACN,reflux 
A /OH 
~~ 
34 
The acetonitrile was removed in vacuum, and the resulting 
residue was partitioned between ether and water. The aque-
ous layer was washed extensively with ether until no 
hydroxypropanylpyridine was left in the aqueous layer. The 
5 resulting aqueous solution of the product was extracted with 
chloroform. The chloroform was removed to afford the 
product (60%). lHNMR (300 MHz, CDC13, ppm), 9.46 (s, 
lH), 9.04 (d, 1=6.0, lH), 8.33 (d, 1=8.1, lH), 7.92 (dd, 1=6.0, 
1=8.1, lH), 7.16 (d, 1=8.4, 2H), 7.04 (d, 1=8.1, 2H), 5.12 (t, 
10 1=6.6, 2H), 3.57 (t, 6.0, 2H), 3.22 (t, 1=6.0, 2H), 2.98 (t, 
1=7.2, 2H), 2.54 (t, 1=7.5, 3H), 1.94 (p, 6.0, 2H), 1.47-1.57 
(m, 2H), 1.26-1.34 (m, 2H), 0.89 (t, 1=7.5, 3H); 13CNMR, 
145.54, 144.99, 143.62, 141.83, 131.20, 128.32, 126.94, 
118.95, 85.65, 82.43, 59.92, 59.78, 58.26, 35.44, 33.28, 
15 32.33, 29.24, 22.68, 22.23, 18.39, 13.88. 
Example 29 
1-(4-Bromo-but-1-ynyl)-4-butyl-benzene (1 mmol) was 
added to a solution of3-hydroxypropanylpyridine (2 mmol) 20 
in acetonitrile, and the solution was refluxed for 24 hours. 
Synthesis of compound 
3-methyl-1-(13-pyridin-3-yl-tridecyl)-pyridinium 
bromide 
35 
Br 
0( 
J~ 
3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
3-picoline (5 ml), and the mixture was heated at 50 C 
overnight. The excess picoline was removed in vacuum, and 
the resulting residue was partitioned between water and 
40 ether. The aqueous layer was washed extensively with ether 
until no picoline left in the aqueous layer, and then the 
aqueous layer was extracted with chloroform. The chloro-
form was removed to afford the product (65%). 1HNMR 
(300 MHz, CDC13, ppm), 9.36 (s, lH), 9.22 (d, 1=5.4, lH), 
45 8.44 (br, 2H), 8.21 (d, 1=7.5, lH), 7.97 (m, lH), 7.54 (d, 7.2, 
lH), 7.24-7.24 m, lH), 4.96 (t, 1=7.2, 2H), 2.58-2.65 M, 
5H), 2.00-2.07 (m, 4H), 1.58-1.60 (m, 2H), 1.20-1.36 (m, 
16H); 13CNMR, 148.76, 146.10, 145.58, 144.77, 142.38, 
139.83, 137.29, 127.80, 123.98, 62.28, 58.71, 33.31, 32.36, 
50 31.32, 29.80, 29.74, 29.64, 29.38, 29.35, 26.45, 19.15, 
18.81. 
Example 30 
Synthesis of compound 3,4-dimethyl-1-(13-pyridin-
3-yl-tridecyl)-pyridinium bromide 
& 
Br N 
US 9,550,753 B2 
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-continued 
3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
3,4-lutidine (5 ml), and the mixture was heated at 50 C 
overnight. The excess picoline was removed in a vacuum, 
and the resulting residue was partitioned between water and 
ether. The aqueous layer was washed extensively with ether 
until no 3,4-lutidine was left in the aqueous layer, and then 15 
the aqueous layer was extracted with chloroform. The chlo-
roform was removed to afford the product (60%). 1HNMR 
(300 MHz, CDC13, ppm), 9.23 (s, lH), 9.04 (d, 1=6.3, lH), 
8.40 (br, 2H), 7.79 (d, 1=6.0, lH), 7.48 (d, 8.1, lH), 
7.18-7.20 (m, lH), 4.83 (t, 1=7.5, 2H), 2.58 (t, 1=7.5, 2H), 
2.52 (s, 3H), 2.49 (s, 3H), 2.21 (br, lH), 1.82-2.02 (m, 2H), 
1.54-1.62 (m, 2H), 1.15-1.35 (br, 12H). 13CNMR, 157.61, 
149.68, 146.92, 143.35, 141.91, 138.45, 138.33, 136.32, 
128.65, 123.57, 61.37, 33.31, 32.19, 31.41, 29.85, 29.80, 
29.68, 29.41, 26.45, 20.69, 17.40. 
10 
20 
25 
Example 31 
Synthesis of compound 3,5-dimethyl-1-(13-pyridin-
3-yl-tridecyl)-pyridinium bromide 
36 
CC.~ I# 
until no 3,5-lutidine was left in the aqueous layer, and then 
the aqueous layer was extracted with chloroform. The chlo-
roform was removed to afford the product (62%). 1HNMR 
(300 MHz, CDC13, ppm), 9.10 (s, 2H), 8.45 (br, 2H), 7.96 
(s, lH), 7.57 (d, 1=7.5, lH), 7.24-7.27 (m, lH), 4.89 (t, 
1=7.5, 2H), 2.59-2.54 (m, SH), 1.99-2.04 (m, 2H), 1.57-1.62 
(m, 2H), 1.21-1.38 (m, ISH), 13CNMR, 148.07, 146.11, 
145.45, 141.94, 139.01, 137.96, 124.16, 62.13, 58.74, 33.29, 
32.34, 31.26, 29.76, 29.73, 29.62, 29.39, 29.30, 26.49, 
18.98, 18.82. 
Example 32 
Synthesis of compound 2-(13-pyridin-3-yl-tridecyl)-
5,6,7,8-tetrahydro-isoquinolinium bromide 
u 
Br N 
3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
3,5-lutidine (5 ml), and the mixture was heated at 50 C 
overnight. The excess picoline was removed in a vacuum, 
50 
and the resulting residue was partitioned between water and 
ether. The aqueous layer was washed extensively with ether 
~ 
Q 
N 
~ 
Q 
N 
c9 
Br N 
0) I# 
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-continued 
Br 
5-(1,1'-biphenyl-4-yl)-4-pentyn-1-ol (3.40 g, 14.39 
mmol) and carbon tetrabromide (6.21 g, 18.71 mmol) were 
dissolved in dry methylene chloride (20 mL) and cooled to 
oo C. Triphenylphosphine (5.15 g, 19.65 mmol) in meth-
3-(13-Bromo-tridecyl)-pyridine (1 mmol) was added to 
5,6,7,8-tetrahydro-isoquinoline (5 ml), and the mixture was 
heated at 50 C overnight. The resulting residue was treated 
with ether, and the ether was decanted after deposition for 
30'. The residue was partitioned between water and ether. 5 The aqueous layer was washed extensively with ether, and 
then the aqueous layer was extracted with chloroform. The 
chloroform was removed to afford the product (62%). 
1HNMR (300 MHz, CDC13, ppm), 9.22 (s, lH), 8.90 (d, 
1=6.3, lH), 8.44 (br, 2H), 7.67 (d, 1=6.3, lH), 7.55 (d, 8.1, 
7.24-7.28 (m, lH), 4.83 (t, 1=7.2, 2.98-3.01 (m, 4H), 2.60 (t, 10 
1=7.8, 2H), 1.94-2.02 (m, 2H), 1.87-1.90 (m, 4H), 1.56-1.60 
(m, 2H), 1.19-1.35 (br, 20H); 13CNMR, 157.87, 148.79, 
146.13, 144.20, 140.68, 138.95, 138.80, 137.26, 128.08, 
123.92, 61.40, 58.62, 33.30, 32.20, 31.34, 29.94, 29.82, 
29.77, 29.67, 29.42, 29.36, 26.71, 26.46, 21.40, 18.81. 
15 y lene chloride ( 10 mL) was added dropwise, and the mixture 
was stirred for 1 h at oo C. The mixture was poured into 
hexanes (100 mL), and then filtered through a short silica gel 
colunm, washed with ethylacetatelhexanes (1/4). The com-
bined organic solvents were evaporated to dryness under 
Example 33 
Synthesis of compound 5-(1,1'-biphenyl-4-yl)-pent-
4-yn-1-ol 
Br 
-
OH 
4-Bromobiphenyl (10.28 g, 44.10 mmol), 4-pentyn-1-ol 
( 4.45 g, 52.92 mmol), and bis(triphenylphosphine )palladium 
(II) dichloride (310 mg, 0.44 mmol) were stirred in trieth-
ylamine (100 mL) under nitrogen for 5 min. Copper(!) 
iodide (42 mg, 0.22 mmol) was added, and the mixture was 
stirred for 4 hrs at 65° C. The mixture was cooled to room 
temperature and filtered through a celite pad, rinsed with 
ethylacetate. The combined filtrate was evaporated to dry-
ness under reduced pressure. The resulting residue was 
purified by colunm chromatography (hexanes:ethylacetate 
3:2) to afford 7.78 g of the title compound. Yield: 75%. 1H 
NMR (300 MHz, CDC13 ) o 1.88 (m, 2H), 2.57 (t, 1=6.9 Hz, 
2H), 3.84 (t, 1=6.0 Hz, 2H), 7.32-7.60 (m, 9H) ppm; 13C 
NMR (75 MHz, CDC13 ) o16.4, 31.7, 62.1, 81.2, 90.2, 122.8, 
127.0, 127.1, 127.6, 128.9, 132.0, 140.1 ppm. 
Example 34 
Synthesis of compound 
4-(5-bromo-pent-1-ynl)-1, 1 '-biphenyl 
OH 
-
20 reduced pressure. The resulting residue was purified by 
colunm chromatography (hexanes:ethylacetate 30:1) to 
afford 4.20 g of the title compound. Yield: 97%. 1 H NMR 
(300 MHz, CDC13 ) o 2.15 (m, 2H), 2.63 (t, 1=6.9 Hz, 2H), 
3.60 (t, 1=6.3 Hz, 2H), 7.32-7.60 (m, 9H) ppm; 13C NMR 
25 (75 MHz, CDC13 ) o 18.5, 31.8, 32.8, 81.7, 88.8, 122.6, 
127.0, 127.1, 127.6, 128.9, 132.1, 140.5, 140.6 ppm. 
30 
35 
40 
45 
50 
Example 35 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent -4-yny 1]-2-methy 1-pyridinium bromide 
Br 
-~ 
# 
D 
Br e 
55 A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (357 
mg, 1.19 mmol) and 2-picoline (1 mL) was heated at 60-70° 
C. for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
60 was removed by lyophilization to afford 393 mg of the title 
compound. Yield: 84%. 1H NMR (300 MHz, CDC13 ) o2.31 
(m, 2H), 2.75 (t, 1=6.3 Hz, 2H), 3.04 (s, 3H), 5.14 (t, 1=7.8 
Hz, 2H), 7.30-7.59 (m, 9H), 7.94-8.01 (m, 2H), 8.38 (t, 
1=7.8 Hz, lH), 9.82 (d, 1=6.0 Hz, lH) ppm; 13C NMR (75 
65 MHz, CDC13 ) o 16.9, 21.1, 29.7, 57.2, 82.4, 88.1, 121.8, 
126.4, 127.0, 127.1, 127.7, 128.9, 130.3, 132.0, 140.1, 
140.8, 145.3, 146.8, 154.6 ppm. 
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Example 36 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-3-methyl-pyridinium bromide 
40 
compound. Yield: 92%. 1 H NMR (300 MHz, CDC13 ) o 2.40 
(m, 2H), 2.49 (s, 3H), 2.67 (t, 1=6.6 Hz, 2H), 5.16 (t, 1=6.9 
Hz, 2H), 7.30-7.59 (m, 9H), 7.80 (d, 1=6.3 Hz, 2H), 9.43 (d, 
1=6.3 Hz, 2H) ppm; 13C NMR (75 MHz, CDC13 ) o 16.8, 
5 22.4, 30.3, 60.3, 82.3, 88.0, 121.9, 126.9, 127.0, 127.8, 
128.8, 129.0, 132.0, 140.1, 140.7, 144.5, 159.2 ppm. 
Br 
0 Br 
--
t) 
10 
15 
20 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (377 25 
mg, 1.26 mmol) and 3-picoline (1 mL) was heated at 60-70° 
C. for 12 hrs. The resulting mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 433 mg of the title 30 
compound. Yield: 88%. 1H NMR (300 MHz, CDC13 ) o2.43 
(m, 2H), 2.58 (s, 3H), 2.67 (t, 1=6.6 Hz, 2H), 5.16 (t, 1=6.9 
Hz, 2H), 7.30-7.61 (m, 9H), 7.98 (dd, 1=8.1, 6.0 Hz, lH), 
8.16 (d, 1=8.1 Hz, lH), 9.37 (d, 1=6.0 Hz, lH), 9.50 (s, lH) 
ppm; 13C NMR (75 MHz, CDC13 ) o 16.8, 19.0, 30.5, 60.9, 35 
82.4, 88.0, 121.9, 126.9, 127.7, 127.8, 128.9, 132.0, 139.7, 
140.1, 140.7, 142.5, 144.8, 145.8 ppm. 
Example 37 
Example 38 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-2,4-dimethyl-pyridinium bromide 
Br 
0 Br 
--
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (328 
mg, 1.10 mmol) and 2,4-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulting mixture was washed with 
diethyl ether, and then dissolved in water (15 mL). The 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-4-methyl-pyridinium bromide 
40 aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 360 
mg of the title compound. Yield: 81%. 1 H NMR (300 MHz, 
CDC13 ) o2.29 (m, 2H), 2.51 (s, 3H), 2.73 (t, 1=6.3 Hz, 2H), 
2.96 (s, 3H), 5.04 (t, 1=7.5 Hz, 2H), 7.30-7.60 (m, 9H), 7.70 
0 Br 
Br 
--
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (360 
45 (s, 2H), 9.56 (d, 1=7.2 Hz, lH) ppm; 13C NMR (75 MHz, 
CDC13 ) o 16.8, 20.7, 22.1, 29.4, 56.4, 82.2, 88.1, 121.8, 
126.9, 127.0, 127.7, 128.9, 130.5, 131.9, 140.0, 140.7, 
145.8, 153.3, 158.7 ppm. 
50 
60 
Example 39 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-3,4-dimethyl-pyridinium bromide 
Br 
--mg, 1.20 mmol) and 4-picoline (1 mL) was heated at 60-70° ~ 
C. for 12 hrs. The resulted mixture was washed with diethyl I 
ether and then dissolved in water (15 mL). The aqueous 65 # 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 435 mg of the title 
US 9,550,753 B2 
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-continued 
e Br 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (327 
mg, 1.09 mmol) and 3,4-lutidine (1 mL) was heated at 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL). The 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 380 
mg of the title compound. Yield: 86%. 1 H NMR (300 MHz, 
CDC13 ) o 2.36 (s, 3H), 2.43 (s, 3H), 2.55 (m, 2H), 2.69 (t, 
1=6.6 Hz, 2H), 5.10 (t, 1=6.6 Hz, 2H), 7.28-7.59 (m, 9H), 
7.77 (d, 1=6.0 Hz, lH), 9.22 (d, 1=6.0 Hz, lH), 9.38 (s, lH) 
ppm; 13C NMR (75 MHz, CDC13 ) o 16.8, 17.2, 20.4, 30.2, 
60.1, 82.0, 88.2, 122.0, 126.9, 127.7, 128.5, 128.9, 131.9, 
138.2, 140.0, 140.6, 142.1, 143.7, 157.9 ppm. 
Example 40 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-3,5-dimethyl-pyridinium bromide 
Br 
-
10 
15 
20 
25 
42 
Example 41 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-quinolinium bromide 
Br 
-
~ 
# 
8 N 
~ Br e 
# 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (329 
mg, 1.10 mmol) and quinoline (1 mL) was heated at 60-70° 
C. for 12 hrs. The resulted mixture was washed with diethyl 
30 ether and then dissolved in water (30 mL). The aqueous 
solution was extracted with ethyl acetate (30 mLx3). Water 
was removed by lyophilization to afford 328 mg of the title 
compound. Yield: 70%. 1 H NMR (300 MHz, CDC13 ) o 2.49 
35 
(m, 2H), 2.84 (t, 1=6.3 Hz, 2H), 5.67 (t, 1=7.2 Hz, 2H), 
7.22-7.62 (m, 9H), 7.93 (t, 1=7.5 Hz, lH), 8.10-8.21 (m, 
2H), 8.34 (d, 1=7.5 Hz, lH), 8.63 (d, 1=9.0 Hz, lH), 9.11 (d, 
1=8.1 Hz, lH), 10.60 (d, 1=5.4 Hz, lH) ppm; 13C NMR (75 
MHz, CDC13 ) o 17.1, 29.1, 57.0, 82.2, 88.4, 118.4, 121.8, 
40 122.5, 126.9, 127.7, 128.9, 130.0, 130.2, 131.2, 131.9, 
136.2, 137.8, 140.0, 140.7, 147.5, 150.5 ppm. 
Example 42 
e Br 
~~~ Y" Synthesis of compound 2-[5-(1,1 '-biphenyl-4-yl)-pent-4-ynyl]-isoquinolinium bromide 
50 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (360 
mg, 1.20 mmol) and 3,5-lutidine (1 mL) was heated at 
55 
I 
60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (15 mL). The 
aqueous solution was extracted with diethyl ether (30 
mLx3). Water was removed by lyophilization to afford 439 
60 
mg of the title compound. Yield: 90%. 1 H NMR (300 MHz, 
CDC13 ) o 2.43 (m, 2H), 2.54 (s, 6H), 2.67 (t, 1=6.6 Hz, 2H), 
5.10 (t, 1=6.9 Hz, 2H), 7.30-7.60 (m, 9H), 7.90 (s, lH), 9.24 
(s, 2H) ppm; 13C NMR (75 MHz, CDC13 ) o16.8, 18.8, 30.4, 65 
e Br 
Br 
-
60.7, 82.3, 88.1, 122.0, 127.0, 127.8, 129.0, 132.0, 138.9, 
140.1, 140.8, 142.1, 146.4 ppm. 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (325 
mg, 1.09 mmol) and isoquinoline (1 mL) was heated at 
US 9,550,753 B2 
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60-70° C. for 12 hrs. The resulted mixture was washed with 
diethyl ether and then dissolved in water (30 mL). The 
aqueous solution was extracted with ethyl acetate (30 
mLx3). Water was removed by lyophilization to afford 340 
mg of the title compound. Yield: 73%. 1H NMR (300 MHz, 5 
CDC13 ) o2.51 (m, 2H), 2.72 (t, 1=6.3 Hz, 2H), 5.34 (t, 1=6.6 
Hz, 2H), 7.16 (d, 1=8.7 Hz, lH), 7.30-7.57 (m, 9H), 7.88 (m, 
2H), 8.01 (d, 1=3.9 Hz, lH), 8.29 (d, 1=6.6 Hz, lH), 8.69 (d, 
1=8.4 Hz, lH), 8.87 (d, 1=6.6 Hz, lH), 11.14 (s, lH) ppm; 
13C NMR (75 MHz, CDC13 ) o 16.9, 30.2, 60.8, 82.3, 88.0, 10 121.7, 126.1, 126.8, 126.9, 127.0, 127.7, 127.9, 128.9, 
131.26, 131.32, 131.8, 134.6, 137.0, 140.1, 140.5, 150.9 
ppm. 
Example 43 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-3-butyl-pyridinium bromide 
15 
44 
-continued 
e Br 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (207 
mg, 0.69 mmol) and 3-phenylpyridine (0.4 mL) was heated 
at 60-70° C. for 12 hrs. The resulted mixture was washed 
with diethyl ether, and then dissolved in water (30 mL). The 
aqueous solution was extracted with ethyl acetate (30 
mLx5). Water was removed by lyophilization to afford 206 
mg of the title compound. Yield: 66%. 1 H NMR (300 MHz, 
Br 
-
20 CD30D) o 2.37 (m, 2H), 2.67 (t, 1=6.3 Hz, 2H), 4.93 (t, 
1=6.9 Hz, 2H), 7.18-7.59 (m, 12H), 7.74 (m, 2H), 8.09 (dd, 
1=8.1, 6.0 Hz, lH), 8.65 (d, 1=8.1 Hz, lH), 9.05 (d, 1=5.7 
Hz, lH), 9.46 (s, lH) ppm; 13C NMR (75 MHz, CD30D) o 
25 17.5, 30.9, 62.6, 82.9, 89.2, 123.2, 127.7, 128.5, 128.7, 
129.4, 130.0, 130.6, 131.4, 133.1, 134.2, 141.0, 141.6, 
e Br 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (254 
mg, 0.85 mmol) and 3-n-butylpyridine (0.5 mL) was heated 
30 
35 
at 60-70° C. for 12 hrs. The resulted mixture was washed 40 
with diethyl ether and then dissolved in water (20 mL). The 
aqueous solution was extracted with ethyl acetate (30 
mLx3). Water was removed by lyophilization to afford 263 
mg of the title compound. Yield: 71%. 1 H NMR (300 MHz, 
CDC13 ) o 0.91 (t, 1=7.2 Hz, 3H), 1.36 (m, 2H), 1.63 (m, 2H), 
2.44 (m, 2H), 2.67 (t, 1=6.6 Hz, 2H), 2.84 (t, 1=7.8 Hz, 2H), 45 
5.22 (t, 1=6.9 Hz, 2H), 7.28-7.63 (m, 9H), 8.04 (dd, 1=7.8, 
6.0 Hz, lH), 8.17 (d, 1=8.1 Hz, lH), 9.39 (s, lH), 9.49 (d, 
1=5.7 Hz, lH) ppm; 13C NMR (75 MHz, CDC13 ) o 14.0, 
16.7, 22.4, 30.5, 32.5, 32.6, 60.9, 82.4, 88.0, 121.9, 126.9, 
127.7, 128.0, 128.9, 132.0, 140.1, 140.8, 142.9, 144.2, 50 
144.3, 144.9 ppm. 
Example 44 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent -4-yny 1]-3-pheny 1-pyridinium bromide 55 
142.3, 144.0, 144.2 ppm. 
Example 45 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pent-4-ynyl]-1-pyridinium bromide 
A mixture of 4-(5-bromo-1-pentynl)-1,1'-biphenyl (162 
mg, 0.54 mmol) and pyridine (1 mL) was heated at 60-70° 
C. for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (10 mL). The aqueous 
solution was extracted with ethyl acetate (30 mLx3). Water 
Br 
-
60 was removed by lyophilization to afford 195 mg of the title 
compound. Yield: 95%. 1 H NMR (300 MHz, CDC13 ) o 2.42 
(m, 2H), 2.67 (t, 1=6.6 Hz, 2H), 5.21 (t, 1=6.9 Hz, 2H), 
7.23-7.62 (m, 9H), 8.10 (t, 1=6.9 Hz, 2H), 8.43 (t, 1=7.8 Hz, 
65 2H), 9.64 (d, 1=6.0 Hz, 2H) ppm; 13C NMR (75 MHz, 
CDC13 ) o 16.7, 30.5, 60.9, 82.3, 87.8, 121.8, 126.8, 127.6, 
128.4, 128.8, 132.0, 139.9, 140.6, 145.27, 145.32 ppm. 
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Example 46 
Synthesis of compound [1,1'-biphenyl]-4-pentanol 
46 
phy (hexanes:ethylacetate 30:1) to afford 4.18 g of the title 
compound. Yield: 99%. 1H NMR (300 MHz, CDC13 ) o1.52 
(m, 2H), 1.67 (m, 2H), 1.91 (m, 2H), 2.67 (t, 1=7.5 Hz, 2H), 
3.41 (t, 1=6.9 Hz, 2H), 7.21-7.60 (m, 9H) ppm; 13C NMR 
5 (75 MHz, CDC13 ) o 28.2, 30.9, 33.0, 34.1, 35.6, 127.1, 
127.2, 128.8, 128.9, 138.8, 141.2, 141.5 ppm. 
OH 
-
10 
OH 15 
20 
5-(1 ,1 '-biphenyl-4-yl)-4-pentyn-1-ol (3.89 g, 16.46 
mmol) was dissolved in methanol (30 mL), and 10% Pd!C 
(2.5% w/w) was added. The resulting mixture was hydro-
genated on a Parr hydrogenation apparatus ( 45 psi) for 4 hrs. 25 
The catalyst was removed by filtration through a Celite pad. 
The filter cake was rinsed with methanol, and the combined 
organic liquors were concentrated under reduced pressure. 
The crude product was purified by colunm chromatography 
30 (hexanes:ethyl acetate 1:1) to afford 3.48 g of the title 
compound. Yield: 88%. 1 H NMR (300 MHz, CDC13 ) o 
1.35-1.48 (m, 3H), 1.55-1.74 (m, 4H), 2.66 (t, 1=7.5 Hz, 
2H), 3.64 (t, 1=6.6 Hz, 2H), 7.21-7.60 (m, 9H) ppm; 13C 
NMR (75 MHz, CDC13 ) o 25.7, 31.5, 32.9, 35.8, 63.1, 35 
127.08, 127.13, 128.8, 128.9, 138.7, 141.2, 141.8 ppm. 
Example 47 
Example 48 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-2-methyl-pyridinium bromide 
Br 
-
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (358 mg, 
1.18 mmol) and 2-picoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulting mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 393 mg of the title 
compound. Yield: 84%. 1H NMR (300 MHz, CDC13 ) o1.53 
(m, 2H), 1.71 (m, 2H), 1.95 (m, 2H), 2.65 (t, 1=7.5 Hz, 2H), 
2.92 (s, 3H), 4.83 (t, 1=8.1 Hz, 2H), 7.20-7.60 (m, 9H), 
7.89-8.02 (m, 2H), 8.38 (d, 1=7.5 Hz, lH), 9.53 (d, 1=6.0 Hz, 
Synthesis of compound 
4-(5-bromopentyl)-1 ,1 '-biphenyl 40 
lH) ppm; 13C NMR (75 MHz, CDC13 ) o 20.9, 25.9, 30.6, 
30.8, 35.2, 58.3, 126.3, 126.8, 126.9, 127.0, 128.7, 128.8, 
130.3, 138.5, 140.7, 140.9, 145.2, 146.3, 154.1 ppm. 
OH 45 
-
50 
Br 
Example 49 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-3-methyl-pyridinium bromide 
Br 
-
55 I 
[1,1'-biphenyl]-4-pentanol (3.34 g, 13.90 mmol) and car-
bon tetrabromide (5.99 g, 18.07 mmol) were dissolved in dry 
methylene chloride (20 mL) and cooled to oo C. Triphenyl 60 
phosphine (4.98 g, 18.07 mmol) in methylene chloride (10 
mL) was added dropwise, and the mixture was stirred for 1 
hat oo C. The mixture was poured into hexanes (100 mL) 
and then filtered through a short silica gel colunm, washed 
with ethylacetatelhexanes (1/4). The combined organic sol- 65 
vents were evaporated to dryness under reduced pressure. 
The resulting residue was purified by colunm chromatogra-
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (358 mg, 
1.18 mmol) and 3-picoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
US 9,550,753 B2 
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (331 mg, 
1.09 mmol) and 2,4-lutidine (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 342 mg of the title 
compound. Yield: 77%. 1H NMR (300 MHz, CDC13 ) o1.51 
(m, 2H), 1.71 (m, 2H), 1.92 (m, 2H), 2.55 (s, 3H), 2.65 (t, 
1=7.8 Hz, 2H), 2.84 (s, 3H), 4.73 (t, 1=7.8 Hz, 2H), 7.20-
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 421 mg of the title 
compound. Yield: 90%. 1H NMR (300 MHz, CDC13 ) o1.45 
(m, 2H), 1.70 (m, 2H), 2.08 (m, 2H), 2.59 (s, 3H), 2.63 (t, 
1=7.5 Hz, 2H), 4.92 (t, 1=7.5 Hz, 2H), 7.18-7.58 (m, 9H), 5 
7.94 (t, 1=7.2 Hz, lH), 8.17 (d, 1=8.1 Hz, lH), 9.26 (d, 1=6.3 
Hz, lH), 9.46 (s, lH) ppm; 13C NMR (75 MHz, CDC13 ) o 
18.8, 25.7, 30.7, 31.9, 35.2, 61.5, 126.8, 126.9, 127.0, 127.7, 
128.3, 128.7, 128.8, 138.5, 139.5, 140.7, 141.1, 142.1, 
144.5, 145.5 ppm. 10 7.75 (m, llH), 9.31 (d, 1=6.3 Hz, lH) ppm; 13C NMR (75 
MHz, CDC13 ) o 20.1, 22.0, 25.8, 30.5, 30.8, 35.2, 57.4, 
126.7, 126.9, 127.0, 128.2, 128.6, 128.8, 130.4, 138.5, 
140.7, 140.9, 145.4, 152.8, 158.4 ppm. 
Example 50 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-4-methyl-pyridinium bromide 
Br 
15 
-- 20 
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (348 mg, 
1.15 mmol) and 4-picoline (1 mL) was heated at 60-70° C. 
30 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 35 
was removed by lyophilization to afford 391 mg of the title 
compound. Yield: 86%. 1 H NMR (300 MHz, CDC13 ) o 1.42 
(m, 2H), 1.69 (m, 2H), 2.04 (m, 2H), 2.57 (s, 3H), 2.62 (t, 
1=7.2 Hz, 2H), 4.85 (t, 1=7.2 Hz, 2H), 7.15-7.62 (m, 9H), 
7.82 (d, 1=6.0 Hz, 2H), 9.25 (d, 1=6.0 Hz, 2H) ppm; 13C 40 
NMR (75 MHz, CDC13 ) o 22.3, 25.5, 30.7, 31.6, 35.2, 61.0, 
126.8, 126.9, 127.1, 128.7, 128.8, 128.9, 138.5, 140.7, 
141.1, 144.0, 158.7 ppm. 
Example 52 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-3,4-dimethyl-pyridinium bromide 
Br 
--
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (322 mg, 
1.06 mmol) and 3,4-lutidine (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 
was removed by lyophilization to afford 380 mg of the title 
compound. Yield: 87%. 1 H NMR (300 MHz, CDC13 ) o 1.43 
(m, 2H), 1.69 (m, 2H), 2.05 (m, 2H), 2.46 (s, 3H), 2.48 (s, 
3H), 2.62 (t, 1=7.5 Hz, 2H), 4.82 (t, 1=7.2 Hz, 2H), 7.18-7.58 
(m, 9H), 7.76 (d, 1=6.3 Hz, lH), 9.07 (d, 1=6.3 Hz, lH), 9.29 
(s, lH) ppm; 13C NMR (75 MHz, CDC13 ) o17.1, 20.4, 25.6, 
30.7, 31.7, 35.2, 60.7, 126.8, 126.9, 127.0, 128.4, 128.7, 
Example 51 45 128.8, 138.2, 138.5, 140.7, 141.1, 141.7, 143.3, 157.4 ppm. 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-2,4-dimethyl-pyridinium bromide 
Br 
--
50 
55 
~"' N 
~ # 
65 
# 
I 
Example 53 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-3,5-dimethyl-pyridinium bromide 
Br 
--~ 
# 
~ 
# 
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A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (352 mg, 
1.16 mmol) and 3,5-lutidine (1 mL) was heated at 60-70° C. 
50 
-continued 
for 12 hrs. The resulting mixture was washed with diethyl 
ether and then dissolved in water (15 mL). The aqueous 
solution was extracted with diethyl ether (30 mLx3). Water 5 
was removed by lyophilization to afford 406 mg of the title 
compound. Yield: 85%. 1 H NMR (300 MHz, CDC13 ) o 1.45 
(m, 2H), 1.70 (m, 2H), 2.08 (m, 2H), 2.53 (s, 6H), 2.63 (t, 
1=7.8 Hz, 2H), 4.84 (t, 1=7.5 Hz, 2H), 7.18-7.58 (m, 9H), 
7.93 (s, lH), 9.21 (s, lH) ppm; 13C NMR (75 MHz, CDC13 ) 10 
0 18.6, 25.8, 30.8, 31.9, 35.2, 61.3, 126.8, 126.9, 127.0, 
128.7, 128.8, 138.4, 138.7, 140.7, 141.1, 141.7, 146.0 ppm. 
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (322 mg, 
1.06 mmol) and isoquinoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulted mixture was washed with diethyl 
ether and then dissolved in water (30 mL). The aqueous 
Example 54 
Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-
pentyl]-quinolinium bromide 
Br 
--
15 solution was extracted with ethyl acetate (30 mLx5). Water 
was removed by lyophilization to afford 278 mg of the title 
compound. Yield: 61%. 1 H NMR (300 MHz, CDC13 ) o 1.47 
(m, 2H), 1.70 (m, 2H), 2.17 (m, 2H), 2.61 (t, 1=7.5 Hz, 2H), 
5.07 (t, 1=7.5 Hz, 2H), 7.14-7.55 (m, 9H), 7.86 (m, lH), 8.05 
20 (m, 2H), 8.33 (d, 1=6.9 Hz, lH), 8.70 (d, 1=8.1 Hz, lH), 8.79 
(dd, 1=6.9, 0.6 Hz, lH), 10.93 (s, lH) ppm; 13C NMR (75 
MHz, CDC13 ) o 25.7, 30.7, 31.7, 35.2, 61.5, 126.3, 126.8, 
126.9, 127.0, 127.7, 128.7, 128.8, 131.15, 131.22, 134.4, 
25 136.9, 137.2, 138.5, 140.8, 141.0, 150.1 ppm. 
8 30 N + # Example 56 Synthesis of compound 1-[5-(1,1'-biphenyl-4-yl)-penty 1]-3 -buty 1-pyridinium bromide 
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (328 mg, 
1.08 mmol) and quinoline (1 mL) was heated at 60-70° C. 
for 12 hrs. The resulting mixture was washed with diethyl 
ether and then dissolved in water (30 mL). The aqueous 
solution was extracted with ethyl acetate (30 mLx5). Water 
was removed by lyophilization to afford 297 mg of the title 
compound. Yield: 64%. 1 H NMR (300 MHz, CDC13 ) o 1.58 
(m, 2H), 1.70 (m, 2H), 2.13 (m, 2H), 2.62 (t, 1=7.5 Hz, 2H), 
5.37 (t, 1=7.8 Hz, 2H), 7.14-7.58 (m, 9H), 7.92 (d, 1=7.5 Hz, 
lH), 8.17 (m, 2H), 8.36 (m, 2H), 9.13 (d, 1=8.4 Hz, lH), 
10.33 (d, 1=5.4 Hz, lH) ppm; 13C NMR (75 MHz, CDC13 ) 
0 26.1, 30.3, 30.9, 35.2, 58.1, 118.3, 122.5, 126.8, 126.9, 
127.1, 128.7, 128.8, 129.9, 130.1, 131.1, 136.0, 137.5, 
138.5, 140.7, 141.0, 147.3, 150.1 ppm. 
Example 55 
Synthesis of compound 2-[5-(1,1'-biphenyl-4-yl)-
penty 1]-isoquinolinium bromide 
Br 
--
35 
55 
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (360 mg, 
1.19 mmol) and 4-n-butylpyridine (0.5 mL) was heated at 
60-70° C. for 12 hrs. The resulting mixture was washed with 
diethyl ether and then dissolved in water (15 mL). The 
aqueous solution was extracted with ethyl acetate (30 
mLx3). Water was removed by lyophilization to afford 377 
mg of the title compound. Yield: 72%. 1 H NMR (300 MHz, 
CDC13 ) o 0.92 (t, 1=7.2 Hz, 3H), 1.29-1.53 (m, 4H), 1.60-
60 1.80 (m, 4H), 2.08 (m, 2H), 2.63 (t, 1=7.5 Hz, 2H), 2.85 (t, 
1=7.8 Hz, 2H), 4.94 (t, 1=7.5 Hz, 2H), 7.18-7.60 (m, 9H), 
8.00 (t, 1=7.2 Hz, lH), 8.16 (d, 1=8.1 Hz, lH), 9.29 (d, 1=6.0 
Hz, lH), 9.30 (s, lH) ppm; 13C NMR (75 MHz, CDC13 ) o 
65 13.9, 22.3, 25.7, 30.8, 32.0, 32.5, 32.6, 35.2, 61.7, 126.8, 
127.0, 127.1, 128.0, 128.8, 128.9, 138.6, 140.8, 141.1, 
142.5, 144.0, 144.1, 144.6 ppm. 
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Example 57 
Synthesis of compound 
1-[ 5-(1, 1 '-biphenyl-4-yl)-pentyl]-pyridinium 
bromide 
Br 
-
A mixture of 4-(5-bromopentyl)-1,1'-biphenyl (335 mg, 
1.10 mmol) and pyridine (1 mL) was heated at 60-70° C. for 
10 
52 
-continued 
~OH 
ZZ-1-71A ZZ-1-71B 
Sonagashira 
Coupling 
OH 
~ 
I_ +R N~ 
Br 
ZZ-1-71C 
12 hrs. The resulted mixture was washed with diethyl ether 
and then dissolved in water (15 mL). The aqueous solution 
was extracted with diethyl ether (30 mLx3). Water was 
removed by lyophilization to afford 381 mg of the title 
compound. Yield: 90%. 1H NMR (300 MHz, CDC13 ) ll1.44 
(m, 2H), 1.69 (m, 2H), 2.07 (m, 2H), 2.62 (t, 1=7.5 Hz, 2H), 
4.96 (t, 1=7.5 Hz, 2H), 7.15-7.60 (m, 9H), 8.06 (t, 1=6.9 Hz, 30 
2H), 8.42 (d, 1=7.8 Hz, lH), 9.48 (d, 1=6.0 Hz, 2H) ppm; 13C 
NMR (75 MHz, CDC13 ) ll25.6, 30.7, 31.9, 35.2, 61.8, 126.8, 
127.0, 127.1, 128.4, 128.8, 128.9, 138.6, 140.8, 141.0, 145.0 ZZ-1-71D ZZ-1-71E ZZ-1-71F 
ppm. 
Example 58 
Synthesis and Structures of Mono-Quaternary 
Ammonium Compounds Containing 
Phenylene-Acetylenic Moieties in theN-Alkyl 
Substituent 
35co 
~+ 
~Br 
40 
45 
Br ~ 
I_ +R N~ 
ZZ-1-71H 
Example 59 
Synthesis and Structures of Mono-Quaternary 
Ammonium Compounds Containing 
Biphenylene-Acetylenic or Biphenylene-Alkylenic 
Moieties in theN-Alkyl Substituent 
Br 
/'-... 
I_ -}R N~ 
B 
A 
e 
Br 
0 N~ 
I {-R v 
US 9,550,753 B2 
~ 
1. t-R N~ 
A GZ·565A 
B GZ·573A 
53 
GZ·565B 
GZ·573B 
GZ·565C 
GZ·573C 
GZ·566A 
GZ·574·A 
A 
B 
GZ·567C 
GZ·575C 
GZ·568A 
GZ·576A 
GZ·568B 
Example 60 
Synthesis and Structures of Mono-Quaternary 
Ammonium Compounds Containing a Terminal 
3-Pyridinyl Moiety 
() 
N 
"""' N 
~ 
1. t-R N~ 
1 ,ll·dibromoundecane 
LDA 
Br ()_R Nv 
n rrn ~~ ~v ~~Br 
ZZ·1·77A ZZ·1·77B ZZ·1·77C 
OC ~ ~N N r~ lNJ 1 
ZZ·1·77D ZZ·1·77E ZZ·1·77F 
Example 61 
Synthesis and Structures of Oxa Analogs of 
Mono-Quaternary Ammonium Compounds 
~o/'-,./0~0H 
(),_R 
~o~o~clNV 
GZ·566B 
GZ·574B 
GZ·566C 
GZ·574C 
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GZ·567A 
GZ·575A 
GZ·567B 
GZ·575B 
GZ·568C 
GZ·576B 
-continued 
20 ~0~0~~0 
c1 8 I 
# QVCX 
ZZ·lAOA ZZ·lAOB ZZ·lAOC 
ZZ·lAOD ZZ·lAOE ZZ·lAOF ZZ·lAOG 
35 (J() "'N ~0" 
N l.J I ~-) N N 
40 
45 
ZZ-1-40H ZZ-1-40! ZZ-1-40J 
Example 62 
Method for the In Vitro Inhibition of [3 H]Nicotine 
Binding and [3 H]Methyllycaconitine (MLA) 
Binding 
Test compounds of Formula (I), representing the mono 
50 
quaternary nicotine analogs of the present invention, were 
evaluated to determine the effect of a test compound on 
nicotine-binding and methyllycaconitine-binding mediated 
by nicotine acetylcholine receptors. Table 1 of provides the 
results of these binding assays. 
55 Whole brain, excluding cortex and cerebellum, was 
homogenized in 20 volumes of ice-cold buffer containing: 2 
mM HEPES, 11.8 mM NaCl, 0.48 mM KCl, 0.25 mM 
CaC12 , and 0.12 mM MgS04 , pH 7.5. Homogenate was 
centrifuged (25,000 g, 15 min, 4° C.). Pellets were resus-
60 pended in 20 volumes of buffer and incubated at 37° C., for 
10 min, cooled to 4° C. and centrifuged (25,000 g, 15 min, 
4° C.). Pellets were resuspended and centrifuged using the 
same conditions. Final pellets were stored in assay buffer, 
containing: 20 mM HEPES, 118 mM NaCI, 4.8 mM KCl, 
65 2.5 mM CaC12 , and 1.2 mM MgS04 , pH 7.5 at -70° C. Upon 
use, final pellets were resuspended in -20 volumes of assay 
buffer. Samples (250 fll) contained 100-140 flg of membrane 
US 9,550,753 B2 
55 
protein, 3 nM [3H]nicotine or 3 nM [3 H]methyllycaconitine 
(MLA), and test compounds of Formula (I) (100 nM) in 
assay buffer containing 50 mM Tris. A control sample absent 
test compounds of Formula (I) was also prepared. In the 
[ 3H]nicotine-binding assay and [3 H]MLA-binding assay, 5 
nonspecific-binding was determined in the presence of 10 
f.LM nicotine and 10 f.LM MLA, respectively. Incubations 
proceeded for 60 min at a room temperature using 96-well 
plates, and were terminated by harvesting on Unifilter-96 
GF/B filter plates presoaked in 0.5% polyethylenimine, 10 
using a Packard FilterMate harvester. After washing 5 times 
with 350 fll ice-cold assay buffer, the filter plates were dried 
(60 min, 4° C.), bottom-sealed, and filled with Packard's 
MicroScint 20 cocktail (40 fll/well). After 60 min, filter 
plates were top-sealed, and levels of radioactivity were 15 
determined using a Packard TopCount. Protein concentra-
tions were determined using the Bradford dye-binding pro-
cedure using bovine serum albumin as a standard protein. 
56 
samples were collected. Subsequently, S-(-)-nicotine (10 
f.LM) was added to the buffer, and an additional 12 consecu-
tive five minute samples were collected. At the end of the 
experiment, each slice was solubilized, and the [3H] content 
of the tissue determined. 
Radioactivity in the superfusate and tissue samples was 
determined by liquid scintillation spectroscopy. Fractional 
release of tritium collected in each sample was divided by 
the total tritium present in the tissue at the time of sample 
collection, and the fractional release of tritium collected was 
expressed as a percentage of total tritium. Basal [3H]outflow 
was calculated from the average of the tritium collected in 
the two five minute samples just before addition of a test 
compound of Formula (I). The sum of the increase in 
collected tritium resulting from either exposure to a test 
compound of Formula (I), or exposure to S(-) nicotine in the 
absence and presence of a test compound of Formula (I) 
equaled total [3 H]overflow. [3H]Overflow was calculated by 
Example 63 
Method for the Analysis of Rat Striatal Slices for 
Inhibition of Nicotine-Evoked [3H]Neurotransmitter 
Release 
20 subtracting the [3 H]outflow during an equivalent period of 
pre-stimulation from the values in samples collected during 
and after drug exposure. Inasmuch as the radio-labeled 
compounds were not separated and identified, the tritium 
collected in superfusate is referred to as either [3H]outflow 
Rat striatal slices (500 f.tm thickness, 6-8 mg wet weight) 
were incubated for 30 minutes in Krebs buffer (118 mM 
NaCl, 4.7 mM KCl, 1.2 mM MgC12 , 1.0 mM NaH2P04 , 1.3 
mM CaC12 , 11.1 mM glucose, 25 mM NaHC03 , 0.11 mM 
L-ascorbic acid, and 0.004 mM disodium EDTA at pH 7.4, 
and saturated with 95% 0i5% C02 ) in a metabolic shaker 
25 or [3H]overflow, rather than as [3 H]DA. [3H]Overflow pri-
marily represents [3H]DA in the presence of nomifensine 
and pargyline in the superfusion buffer. 
The mono quaternary analogs of Formula (I) were evalu-
ated for their ability to evoke [3H]DA release from rat 
30 striatal slices. In addition, the classical competitive nicotinic 
antagonist DH~E was also examined in this assay for 
comparison. None of the compounds examined had any 
significant [3H]DA releasing properties in this assay in the 
at 34 o C. Slices were rinsed with 15 mL of fresh buffer, and 
were incubated for an additional 30 minutes in fresh buffer 
containing 0.1 f.LM [3H]dopamine (DA; 6 slices/3 mL). 
Subsequently, slices were rinsed with 15 mL of fresh buffer 35 
and transferred to a glass superfusion chamber. Slices were 
superfused (1.0 mL/min) for 60 minutes with Krebs buffer 
containing nomifensine ( 10 f.LM) and pargyline ( 1 0 f.LM), and 
maintained at 34° C., pH 7.4, with continual aeration (95% 
0 2/5% C02 ). Two five minute samples (5 mL each) were 
collected to determine basal outflow of [3H]DA. The test 
compounds of Formula (I) were added to the superfusion 
buffer after the collection of the second sample, and were 
maintained in the buffer until 12 consecutive five minute 
concentration range tested. 
The quaternary analogs of Formula (I) were also evalu-
ated for their ability to inhibit NIC-evoked [3 H]DA release. 
In these experiments, the striatal slices were superfused for 
60 minutes with 100 nM concentration of the quaternary 
analogs prior to NIC (1 0 f.LM) exposure. Antagonist activity 
40 was evaluated by comparing the NIC-evoked [3 H]overflow 
in the absence and presence of the analogs. The relative 
order of potency of the quaternary analogs of Formula (I) for 
inhibition of NIC-evoked [3 H]DA release from rat striatal 
slices is illustrated in Table 1. 
TABLE 1 
Inhibition of [3 H]NIC and [3H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
['H) Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I). 
TEST COMPOUND OF FORMULA (I) 
ZZ-1-49 
e 
Br 
ZZ-1-104 
e 
Br 
Inhibition of 
[3H]Nicotine 
binding 
Qo/oa 
0% 
Inhibition of Inhibition of 
['H]MLA Nicotine-evoked 
binding ['H]DA release 
Qo/oa 62o/oa 
0% ND 
US 9,550,753 B2 
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TABLE !-continued 
Inhibition of [3H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I). 
TEST COMPOUND OF FORMULA (I) 
~> 
( @> 
( @> 
( @> 
~N 
ZZ-1-70 
0 
Br 
ZZ-1-94 
0 
Br 
ZZ-1-137A 
ZZ-1-47 
0 
Br 
ZZ-1-48 
0 
Br 
ZZ-1-71 
0 
Br 
ZZ-1-76 
0 
Br 
Inhibition of Inhibition of 
['H]Nicotine [3H]MLA 
binding binding 
0% 0% 
4% 2% 
0% 2% 
K, > 100 Ki > 100 
Ki > 100 Ki; 
27±11 
6% 3% 
5% 0% 
0% 0% 
Inhibition of 
Nicotine-evoked 
[3H]DA release 
11% 
33% 
31% 
0% 
12% 
11% 
58% 
ND 
US 9,550,753 B2 
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TABLE !-continued 
Inhibition of [3H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I). 
TEST COMPOUND OF FORMULA (I) 
HO~ ® N 
HO~ ® N 
-0 
-0 
--GN 
ZZ-1-74 
e 
Br 
ZZ-1-98 
e 
Br 
ZZ-1-137F 
ZZ-1-77 
e 
Br 
ZZ-1-101 
e 
Br 
ZZ-1-107 
e 
Br 
ZZ-1-50 
e 
Br 
ZZ-1-73 
e 
Br 
Inhibition of 
[3 H]Nicotine 
binding 
Ki > 100 
Ki > 100 
Ki > 100 
0% 
0% 
6% 
0% 
0% 
Inhibition of 
[3H]MLA 
binding 
Ki; 
3.7 ± 0.3 
Ki; 
14 ± 3.7 
Ki; 
7.2 ± 1.0 
0% 
0% 
0% 
9% 
10% 
Inhibition of 
Nicotine-evoked 
[3H]DA release 
70 
ND 
0% 
ND 
64 
19% 
14% 
ND 
US 9,550,753 B2 
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TABLE !-continued 
Inhibition of [3H]NIC and [3 H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula(!). 
Inhibition of Inhibition of 
[3 H]Nicotine [3H]MLA 
TEST COMPOUND OF FORMULA (I) binding binding 
ZZ-1-137D 3% 0% 
ZZ-1-97 0% 0% 
-0 
e 
Br 
ZZ-1-72 0% 0% 
~N e Br 
ZZ-1-96 0% 0% 
~N e Br 
ZZ-1-137C 0% 0% 
~N 
GZ-565B 2% 7% 
0 e le# Br 
~ 
# 
GZ-573B ND ND 
~ 
t) 
# 
Inhibition of 
Nicotine-evoked 
[3H]DA release 
20% 
ND 
ND 
ND 
35% 
45% 
45% 
US 9,550,753 B2 
63 64 
TABLE !-continued 
Inhibition of [3H]NIC and [3 H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I). 
Inhibition of Inhibition of Inhibition of 
[3 H]Nicotine [3H]MLA Nicotine-evoked 
TEST COMPOUND OF FORMULA (I) binding binding [3H]DA release 
GZ-565A 0 2% 41% 
t? e 1(£)# Br ~ 
# 
GZ-573A 4% 7% 55% 
t? ~ 1(£)# # 
GZ-573C ND ND 18% 
~ ~ 1(£)# 
# 
GZ-565C 0% 3% 40% 
~ e 1(£)# Br 
~ 
# 
GZ-566A 8% 3% 51% y e 1(£)# Br 
~ 
# 
GZ-574A ND ND 51% y ~ 1(£)# 
# 
US 9,550,753 B2 
65 66 
TABLE !-continued 
Inhibition of [3H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I). 
Inhibition of Inhibition of Inhibition of 
[3 H]Nicotine [3H]MLA Nicotine-evoked 
TEST COMPOUND OF FORMULA (I) binding binding [3H]DA release 
GZ-566B 0% 8% 20% 
~ e 10# Br ~ 
# 
GZ-574B ND ND 38% 
~ e 10# ~ Br # 
GZ-566C 2% 6% 5% 
Q e 10# Br 
~ 
# 
GZ-574C ND ND 39% 
~ Q 10# 
# 
GZ-567A 1% 7% 23% 
e 0 Br ~ # # 
# 
GZ-575A ND ND 61% 
~ 0 # # # 
US 9,550,753 B2 
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TABLE !-continued 
Inhibition of [3H]NIC and ['H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula (I). 
Inhibition of Inhibition of Inhibition of 
[3 H]Nicotine [3H]MLA Nicotine-evoked 
TEST COMPOUND OF FORMULA (I) binding binding [3H]DA release 
GZ-567B 0% 6% ND 
tO e 1(£)# Br ~ ~I 
# 
GZ-575B 0% 6% ND 
tO ~ 1(£)# ~I # 
GZ-567C 20% 6% 47% 
0 e 1(£)# Br 
~ 
H3C'NQ 
# 
GZ-575C ND ND 51% 
~ 0 1(£)# 
# H3C'NQ 
GZ-568A 0% 9% 50% 
e 
Br 
GZ-576A ND ND 43% 
US 9,550,753 B2 
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TABLE !-continued 
Inhibition of [3H]NIC and [3 H]MLA Binding to Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked 
[3H]Dopamine Release from Superfused Rat Striatal Slices by Mono Quaternary Ammonium Salts of Formula(!). 
TEST COMPOUND OF FORMULA (I) 
GZ-568B 
e 
Br 
~ 
# 
GZ-568C 
0 e 10# Br 
~ 
# 
GZ-576B 
0 10# 
It will be appreciated that, although specific embodiments 
of the invention have been described herein for purposes of 
illustration, various modifications may be made without 40 
departing from the spirit and the scope of the invention. All 
such modifications and variations ore intended to be 
included herein within the scope of this disclosure and the 
present invention and protected by the following claims. 
We claim: 
1. A compound of Formula (I): 
(I) 
wherein A1 , A2 , A3 , A4 , and As are each carbon; 
wherein three of R 1 , R3 , R4 , and Rs are hydrogen, alkyl, 
or substituted alkyl, and 
45 
50 
55 
60 
R 1 and R 2 orR 2 and R3 together with the carbons to which 65 
they are attached independently form a three- to eight-
member cycloalkane, cycloalkene, aryl, heterocycle 
Inhibition of Inhibition of Inhibition of 
[3 H]Nicotine [3H]MLA Nicotine-evoked 
binding binding [3H]DA release 
8% 6% ND 
2% 6% 34% 
ND ND 30% 
with one to three hetero atoms in the ring, or substituted 
heterocycle with one to three hetero atoms in the ring; 
wherein Z1 is absent or is selected from the group con-
sisting of alkyl, substituted alkyl, cycloalkyl, alkenyl, 
alkynyl, phenylene, and alkoxy; 
wherein Z2 is selected from the group consisting of 
substituted alkyl, cycloalkyl, alkenyl, alkynyl, arylene, 
heterocycle, substituted heterocycle, and alkoxy; 
wherein Z3 is selected from propyl, butyl, hexyl, substi-
tuted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, hetero-
cycle, and substituted heterocycle; 
wherein x- is an inorganic or organic anion, 
wherein substituted alkyl is an alkyl substituted with one 
or more substituents selected from the group consisting 
of hydroxy, lower-alkyl alkoxy, lower-alkyl mercapto, 
halogen, trifluoromethyl, cyano, nitro, amino, carboxyl, 
carbamate, sulfonyl, sulfonamide, an aryl group, and a 
heterocyclic group, and 
wherein substituted heterocycle is a heterocycle substi-
tuted with one or more substituents selected from the 
group consisting of hydroxy, lower-alkyl alkoxy, 
lower-alkyl mercapto, halogen, trifluoromethyl, cyano, 
nitro, amino, carboxyl, carbamate, sulfonyl, sulfona-
mide, an aryl group, and a heterocyclic group. 
2. The compound of claim 1, whereinA1 , A2 , A3 , A4 , and 
As are carbon; 
wherein R1 is hydrogen, methyl, forms a six membered 
ring with A 1, A 2 and R 2 and with R 1 and R 2 providing 
four saturated carbon atoms, or forms a phenyl group 
withA1 , A2 and R2 ; 
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wherein R2 is hydrogen, methyl, ethyl, butyl, phenyl, 
3-hydroxypropyl, forms a six membered ring with A 1 , 
A 2 and R 1 and with R 1 and R 2 providing four saturated 
carbon atoms, forms a phenyl group with A\ A2 and 
R\ forms a six membered ring withA2 , A3 and R3 and 5 
with R2 and R3 providing four saturated carbon atoms, 
or forms a phenyl group with A2 , A3 and R3 ; 
wherein R3 is hydrogen, methyl, forms a six membered 
ring withA2 , A3 and R2 and with R2 and R3 providing 
four saturated carbon atoms, or forms a phenyl group 10 
with A2 , A3 and R2 ; 
wherein R4 is hydrogen or methyl; 
wherein R5 is hydrogen; 
wherein Z1 is absent, butyl, but-3-ynyl, pentyl, pent-4-
ynyl or 2-ethoxy; 
wherein Z2 is para-phenylene, or 2-ethoxy; 
wherein Z3 is propyl, butyl, but-1-ynyl, hex-1-ynyl, phe-
nyl, or 3-pyridinyl; 
and wherein X is chloride, bromide or iodide. 
15 
3. The compound of claim 1, wherein A\ A2 , A3 , A4 , and 20 
A5 are carbon; 
wherein R1 is hydrogen, methyl, forms a six membered 
ring with A\ A2 and R2 and with R1 and R2 providing 
four saturated carbon atoms, or forms a phenyl group 
withA1 , A2 and R2 ; 
wherein R2 is hydrogen, methyl, ethyl, 3-hydroxypropyl, 
forms a six membered ring with A 1 , A 2 and R 1 and with 
R 1 and R 2 providing four saturated carbon atoms, forms 
25 
a phenyl group with A1 , A2 and R1 , forms a six 
membered ring withA2 , A3 and R3 and with R2 and R3 30 
providing four saturated carbon atoms, or forms a 
phenyl group with A2 , A3 and R3 ; 
wherein R3 is hydrogen, methyl, forms a six membered 
ring withA2 , A3 and R2 and with R2 and R3 providing 
four saturated carbon atoms, or forms a phenyl group 35 
with A2 , A3 and R2 ; 
wherein R4 is hydrogen or methyl; 
wherein R5 is hydrogen; 
72 
wherein R1 is hydrogen, methyl, or forms a phenyl group 
withA1 , A2 and R2 ; 
wherein R2 is hydrogen, methyl, butyl, forms a phenyl 
group with A 1 , A 2 and R 1 , or forms a pheny I group with 
A2 , A3 and R3 ; 
wherein R3 is hydrogen, methyl, or forms a phenyl group 
with A2 , A3 and R2 ; 
wherein R4 is hydrogen or methyl; 
wherein R5 is hydrogen; 
wherein Z1 is pentyl or pent-4-ynyl; 
wherein Z2 is para-phenylene; 
wherein Z3 is phenyl; and 
wherein X is bromide. 
5. The compound of claim 1 selected from the group 
consisting of: 
2-[ 4-( 4-butyl-phenyl)-butyl]-5,6, 7 ,8-tetrahydro-isoquino-
linium bromide; 
2-[ 4-( 4-butyl-phenyl)-but-3-ynyl]-5,6, 7 ,8-tetrahydro-iso-
quinolinium bromide; 
2-[ 13-(3 -pyridinyl )-tridecy 1]-5 ,6, 7 ,8-tetrahydro-isoqui-
nolinium bromide; 
1-[5-(1,1'-biphenyl-4-yl)-pent-4-ynyl]-quinolinium bro-
mide; 
2-[ 5-(1, 1 '-biphenyl-4-yl)-pent-4-ynyl]-isoquinolinium 
bromide; 
1-[5-(1,1'-biphenyl-4-yl)-pentyl]-quinolinium bromide; 
2-[5-(1,1'-biphenyl-4-yl)-pentyl]-isoquinolinium bro-
mide; 
2-[ 4-( 4-propyl-phenyl)-pent-4-ynyl]-5,6, 7 ,8-tetrahydro-
isoquinolinium bromide; 
1-[2-(2-hexoxy -ethoxy )-ethy 1]-5 ,6, 7 ,8-tetrahydro-quino-
linium chloride; and 
2-[2-(2-hexoxy-ethoxy)-ethyl]-5,6,7,8-tetrahydro-isoqui-
nolinium chloride. 
6. A composition comprising a pharmaceutically accept-
able carrier and a compound of claim 1. 
7. A composition comprising a pharmaceutically accept-
able carrier and a compound of claim 2. 
wherein Z1 is absent, butyl, but-3-ynyl, pent-4-ynyl or 
2-ethoxy; 40 8. A composition comprising a pharmaceutically accept-
able carrier and a compound of claim 3. 
wherein Z2 is para-phenylene, or 2-ethoxy; 
wherein Z3 is propyl, butyl, but-1-ynyl, hex-1-ynyl, phe-
nyl, or 3-pyridinyl; and 
wherein X is chloride, bromide or iodide. 
4.Thecompoundofclaim1,whereinA1 A2 A3 A4 and 45 
A 5 are carbon; ' ' ' ' 
9. A composition comprising a pharmaceutically accept-
able carrier and a compound of claim 4. 
10. A composition comprising a pharmaceutically accept-
able carrier and a compound of claim 5. 
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